AU689184B2

AU689184B2 – BMP-12, BMP-13 and tendon-inducing compositions thereof
– Google Patents

AU689184B2 – BMP-12, BMP-13 and tendon-inducing compositions thereof
– Google Patents
BMP-12, BMP-13 and tendon-inducing compositions thereof

Info

Publication number
AU689184B2

AU689184B2
AU13013/95A
AU1301395A
AU689184B2
AU 689184 B2
AU689184 B2
AU 689184B2
AU 13013/95 A
AU13013/95 A
AU 13013/95A
AU 1301395 A
AU1301395 A
AU 1301395A
AU 689184 B2
AU689184 B2
AU 689184B2
Authority
AU
Australia
Prior art keywords
bmp
seq
ala
leu
arg
Prior art date
1993-12-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Expired

Application number
AU13013/95A
Other versions

AU1301395A
(en

Inventor
Anthony J. Celeste
Douglas A Melton
Vicki A. Rosen
Gerald H Thomsen
Neil M Wolfman
John M. Wozney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Harvard College

Genetics Institute LLC

Original Assignee
Harvard College
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1993-12-07
Filing date
1994-12-06
Publication date
1998-03-26

1994-11-02
Priority claimed from US08/333,576
external-priority
patent/US6027919A/en

1994-12-06
Application filed by Harvard College, Genetics Institute LLC
filed
Critical
Harvard College

1995-06-27
Publication of AU1301395A
publication
Critical
patent/AU1301395A/en

1998-03-26
Application granted
granted
Critical

1998-03-26
Publication of AU689184B2
publication
Critical
patent/AU689184B2/en

2003-02-20
Assigned to PRESIDENT AND FELLOWS OF HARVARD COLLEGE, GENETICS INSTITUTE, LLC
reassignment
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
Request to Amend Deed and Register
Assignors: GENETICS INSTITUTE INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE

2014-12-06
Anticipated expiration
legal-status
Critical

Status
Expired
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

C07K14/475—Growth factors; Growth regulators

C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

C—CHEMISTRY; METALLURGY

C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING

C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA

C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor

C12N15/09—Recombinant DNA-technology

C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES

A61K38/00—Medicinal preparations containing peptides

A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

A61K38/18—Growth factors; Growth regulators

A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/14—Macromolecular materials

A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products

A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix

A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells

A61L27/3839—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by the site of application in the body

A61L27/3843—Connective tissue

A61L27/386—Ligaments, tendons

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES

A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses

A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials

A61L27/54—Biologically active materials, e.g. therapeutic substances

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P1/00—Drugs for disorders of the alimentary tract or the digestive system

A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P17/00—Drugs for dermatological disorders

A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P19/00—Drugs for skeletal disorders

A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P19/00—Drugs for skeletal disorders

A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P19/00—Drugs for skeletal disorders

A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget’s disease

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P5/00—Drugs for disorders of the endocrine system

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07K—PEPTIDES

C07K2319/00—Fusion polypeptide

C07K2319/01—Fusion polypeptide containing a localisation/targetting motif

C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Abstract

Compositions of proteins with tendon/ligament-like tissue inducing activity are disclosed. The compositions are useful in the treatment of tendinitis and tendon or ligament defects and in related tissue repair.

Description

TITLE OF THE INVENTION
BMP-12. BMP-13 AND TENDON-INDUCING COMPOSITIONS THEREOF
RELATED APPLICATIONS
The present invention is a continuation-in-part of application serial number 08/217,780, filed March 25, 1994, 08/164,103, filed on December 7, 1993 and 08\333,576, filed on November 2, 1994.
FIELD OF THE INVENTION The present invention relates to a novel family of purified proteins, and compositions containing such proteins, which compositions are useful for the induction of tendon/ligament-like tissue formation, wound healing and ligament and other tissue repair. These proteins may also be used in compositions for augmenting the activity of bone morphogenetic proteins. BACKGROUND OF THE INVENTION
The search for the molecule or molecules responsible for formation of bone, cartilage, tendon and other tissues present in bone and other tissue extracts has led to the discovery of a novel set of molecules called the Bone Morphogenetic Proteins (BMPs). The structures of several proteins, designated BMP-1 through BMP-11, have previously been elucidated. The unique inductive activities of these proteins, along with their presence in bone, suggests that they are important regulators of bone repair processes, and may be involved in the normal maintenance of bone tissue. There is a need to identify additional proteins which play a role in forming other vital tissues. The present invention relates to the identification of a family of proteins, which have tendon/ligament-like tissue inducing activity, and which are useful in compositions for the induction of tendon/ligament-like tissue formation and repair.
SUMMARY OF THE INVENTION In one embodiment, the present invention comprises DNA molecules encoding a tendon/ligament-like inducing protein which the inventors have named Vl-1. This novel protein is now called BMP-12. The present invention also includes DNA molecules encoding BMP- 12 related proteins.

BMP- 12 related proteins are a subset of the BMP/TGF-β/Vg-1 family of proteins, including BMP- 12 and VL-1, which are defined as tendon/ligament-like tissue inducing proteins encoded by DNA sequences which are cloned and identified, e.g., using PCR, using BMP- 12 specific primers, such as primers #6 and #7 described below, with reduced stringency conditions. It is preferred that the DNA sequences encoding BMP- 12 related proteins share at least about 80% homology at the amino acid level from amino acids with amino acids #3 to #103 of SEQ ID NO: l.
The DNA molecules preferably have a DNA sequence encoding the BMP- 12 protein, the sequence of which is provided in SEQ ID NO: l, or a BMP- 12 related protein as further described herein. Both the BMP- 12 protein and BMP- 12 related proteins are characterized by the ability to induce the formation of tendon/ligament- like tissue in the assay described in the examples.
The DNA molecules of the invention preferably comprise a DNA sequence, as described in SEQUENCE ID NO: 1; more preferably nucleotides #496 to #882, #571 to #882 or #577 to #882 of SEQ ID NO: 1 ; or DNA sequences which hybridize to the above under stringent hybridization conditions and encode a protein which exhibits the ability to form tendon/ligament-like tissue. The DNA molecules of the invention may also comprise a DNA sequence as described in SEQ ID NO: 25; more preferably nucleotides #604 or #658 to #964 of SEQ ID NO:25.
The DNA molecules of the invention also include DNA molecules comprising a DNA sequence encoding a BMP- 12 related protein with the amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 26, as well as naturally occurring allelic sequences and equivalent degenerative codon sequences of SEQ ID NO: 2 or SEQ ID NO: 26. Preferably, the DNA sequence of the present invention encodes amino acids #-25 to # 104, #1 to # 104 or #3 to #103 of SEQ ID NO:2; or amino acids #1 to #120 or #19 to #120 of SEQ ID NO:26. The DNA sequence may comprise, in a 5′ to 3′ direction, nucleotides encoding a propeptide, and nucleotides encoding for amino acids #-25 to #104, #1 to #104 or #3 to #103 of SEQ ID NO:2; or amino acids #1 to #120 or #19 to #120 of SEQ ID NO:26. The propeptide useful in the above embodiment is preferably selected from the group consisting of native BMP- 12 propeptide and a protein propeptide from a different member of the TGF-B
9-

superfamily or BMP family. The invention further comprises DNA sequences which hybridize to the above DNA sequences under stringent hybridization conditions and encode a BMP- 12 related protein which exhibits the ability to induce formation of tendon/ligament-like tissue. In other embodiments, the present invention comprises host cells and vectors which comprise a DNA molecule encoding the BMP-12 protein, or a BMP-12 related protein. The host cells and vectors may further comprise the coding sequence in operative association with an expression control sequence therefor.
In another embodiment, the present invention comprises a method for producing a purified BMP- 12 related protein, said method comprising the steps of culturing a host cell transformed with the above DNA molecule or vector comprising a nucleotide sequence encoding a BMP- 12 related protein; and (b) recovering and purifying said BMP- 12 related protein from the culture medium. In a preferred embodiment, the method comprises (a) culturing a cell transformed with a DNA molecule comprising the nucleotide sequence from nucleotide #496, #571 or #577 to #879 or #882 as shown in SEQ ID NO:l; or the nucleotide sequence from #604 or #658 to #963 of SEQ ID NO:25; and
(b) recovering and purifying from said culture medium a protein comprising the amino acid sequence from amino acid #-25, #1 or #3 to amino acid #103 or #104 as shown in SEQ ID NO:2; or from amino acid #1 or #19 to amino acid #120 as shown in SEQ ID NO: 26. The present invention also includes a purified protein produced by the above methods.
The present invention further comprises purified BMP- 12 related protein characterized by the ability to induce the formation of tendon ligament-like tissue. The BMP- 12 related polypeptides preferably comprise an amino acid sequence as shown in SEQ ID NO:2. The polypeptide more preferably comprise amino acids #-25, #1 or #3 to #103 or #104 as set forth in SEQ ID NO:2; or amino acids #1 or #19 to #120 as set forth in SEQ ID NO:26. In a preferred embodiment, the purified polypeptide may be in the form of a dimer comprised of two subunits, each with the amino acid sequence of SEQ ID NO:2.
In another embodiment, the present invention comprises compositions comprising an effective amount of the above-described BMP- 12 related proteins.

In the compositions, the protein may be admixed with a pharmaceutically acceptable vehicle.
The invention also includes methods for tendon/ligament-like tissue healing and tissue repair, for treating tendinitis, or other tendon or ligament defects, and for inducing tendon ligament-like tissue formation in a patient in need of same, comprising administering to said patient an effective amount of the above composition.
Other embodiments include chimeric DNA molecules comprising a DNA sequence encoding a propeptide from a member of the TGF-β superfamily of proteins linked in correct reading frame to a DNA sequence encoding a BMP- 12 related polypeptide. One suitable propeptide is the propeptide from BMP-2. The invention also includes heterodimeric protein molecules comprising one monomer having the amino acid sequence shown in SEQ ID NO:2, and one monomer having the amino acid sequence of another protein of the TGF-/3 subfamily. Finally, the present invention comprises methods for inducing tendon/ligament-like tissue formation in a patient in need of same comprising administering to said patient an effective amount of a composition comprising a protein which exhibits the ability to induce formation of tendon/ligament-like tissue, said protein having an amino acid sequence shown in SEQ ID NO: 2 or SEQ ID NO: 4 or SEQ ID NO: 26. The amino acid sequences are more preferably one of the following: (a) amino acids #-25, #1 or #3 to #103 or #104 of SEQ ID NO:2; (b) amino acids #1 or #19 to #119 or #120 of SEQ ID NO:4; (c) amino acids #1 or #19 to #119 or #120 of SEQ ID NO:26; (d) mutants and/or variants of (a), (b) or (c) which exhibit the ability to form tendon and/or ligament. In other embodiments of the above method, the protein is encoded by a DNA sequence of SEQ ID NO: l, SEQ ID NO: 3 or SEQ ID NO:25, more preferably one of the following: (a) nucleotides #496, #571 or #577 to #879 or #882 of SEQ ID NO:l; (b) nucleotides #845 or #899 to #1201 or #1204 of SEQ ID NO:3; (c) nucleotides #605 or #659 to #961 or #964 of SEQ ID NO:25; and (d) sequences which hybridize to (a) or (b) under stringent hybridization conditions and encode a protein which exhibits the ability to form tendon/ligament-like tissue. Description of the Sequences
V

SEQ ID NO: l is the nucleotide sequence encoding the human BMP- 12.
SEQ ID NO: 2 is the amino acid sequence comprising the mature human BMP- 12 polypeptide.
SEQ ID NO: 3 is the nucleotide sequence encoding the protein MP52. SEQ ID NO:4 is the amino acid sequence comprising the mature MP52 polypeptide.
SEQ ID NO: 5 is the nucleotide sequence of a specifically amplified portion of the human BMP- 12 encoding sequence.
SEQ ID NO: 6 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:5.
SEQ ID NO: 7 is the nucleotide sequence of a specifically amplified portion of the human VL-1 encoding sequence.
SEQ ID NO: 8 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:7. SEQ ID NO: 9 is the nucleotide sequence of the plasmid pALV 1-781, used for expression of BMP- 12 in E. coli.
SEQ ID NO: 10 is the nucleotide sequence of a fragment of the murine clone, mVl.
SEQ ID NO: 11 is the amino acid sequence of a fragment of the murine protein encoded by mVl .
SEQ ID NO: 12 is the nucleotide sequence of a fragment of the murine clone, mV2.
SEQ ID NO: 13 is the amino acid sequence of a fragment of the murine protein encoded by mV2. SEQ ID NO: 14 is the nucleotide sequence of a fragment of the murine clone, mV9.
SEQ ID NO: 15 is the amino acid sequence of a fragment of the murine protein encoded by mV9.
SEQ ID NO: 16 is the amino acid sequence of a BMP/TGF-β/Vg-1 protein consensus sequence. The first Xaa represents either Gin or Asn; the second Xaa represents either Val or He.
SEQ ID NO: 17 is the nucleotide sequence of oligonucleotide #1.

SEQ ID NO: 18 is the amino acid sequence of a BMP/TGF-/3/Vg-l protein consensus sequence. The Xaa represents either Val or Leu.
SEQ ID NO: 19 is the nucleotide sequence of oligonucleotide #2.
SEQ ID NO: 20 is the nucleotide sequence of oligonucleotide #3. SEQ ID NO :21 is the nucleotide sequence of oligonucleotide #4.
SEQ ID NO: 22 is the nucleotide sequence of oligonucleotide #5
SEQ ID NO: 23 is the nucleotide sequence of oligonucleotide #6.
SEQ ID NO: 24 is the nucleotide sequence of oligonucleotide #7.
SEQ ID NO:25 is the nucleotide sequence of the human VL-1 (BMP-13) encoding sequence.
SEQ ID NO: 26 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 25.
SEQ ID NO: 27 is the nucleotide sequence encoding a fusion of BMP-2 propeptide and the mature coding sequence of BMP- 12. SEQ ID NO:28 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 27.
SEQ ID NO: 29 is the nucleotide sequence encoding the murine mVl protein. XOl is Val, Ala, Glu or Gly; X02 is Ser, Pro Thr or Ala; X03 is Ser or Arg; X04 is Leu, Pro, Gin or Arg; X05 is Cys or Trp; X06 is Val, Ala, Asp or Gly; X07 is Val, Ala, Glu or Gly; X08 is Gin, Lys or Glu.
SEQ ID NO: 30 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 29. XOl through X08 are the same as in SEQ ID NO: 29.
SEQ ID NO: 31 is the nucleotide sequence encoding the murine mV2 protein. XOl is Pro or Thr; X02 is Val. SEQ ID NO: 32 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:31. XOl and X02 are the same as in SEQ ID NO:31.
SEQ ID NO:33 is the nucleotide sequence encoding human BMP-12 protein.
SEQ ID NO: 34 is the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:33. SEQ ID NO: 35 is the nucleotide sequence of oligonucleotide #8.
Brief Description of the Figures
Figure 1 is a comparison of the human BMP- 12 and human MP52 sequences.

Detailed Description of the Invention
The DNA sequences of the present invention are useful for producing proteins which induce the formation of tendon/ ligament-like tissue, as described further below. The DNA sequences of the present invention are further useful for isolating and cloning further DNA sequences encoding BMP- 12 related proteins with similar activity. These BMP- 12 related proteins may be homologues from other species, or may be related proteins within the same species.
Still, a further aspect of the invention are DNA sequences coding for expression of a tendon ligament-like tissue inducing protein. Such sequences include the sequence of nucleotides in a 5′ to 3′ direction illustrated in SEQ ID NO: l or SEQ ID NO:25, DNA sequences which, but for the degeneracy of the genetic code, are identical to the DNA sequence SEQ ID NO:l or 25, and encode the protein of SEQ ID NO: 2 or 26. Further included in the present invention are DNA sequences which hybridize under stringent conditions with the DNA sequence of SEQ ID NO: 1 or 25 and encode a protein having the ability to induce the formation of tendon or ligament. Preferred DNA sequences include those which hybridize under stringent conditions as described in Maniatis et al, Molecular Cloning (A Laboratory Manual), Cold Spring Harbor Laboratory (1982), pages 387 to 389. Finally, allelic or other variations of the sequences of SEQ ID NO: l or 25, whether such nucleotide changes result in changes in the peptide sequence or not, but where the peptide sequence still has tendon/ligament-like tissue inducing activity, are also included in the present invention.
The human BMP- 12 DNA sequence (SEQ ID NO: 1) and amino acid sequence (SEQ ID NO: 2) are set forth in the Sequence Listings. Another protein that is useful for the compositions and methods of the present invention is VL-1. VL-1 is a BMP- 12 related protein which was cloned using sequences from BMP- 12. The inventors have now designated VL-1 as BMP-13. A partial DNA sequence of VL-1 (SEQ ID NO: 7) and the encoded amino acid sequence (SEQ ID NO: 8); as well as a DNA sequence encoding the mature VL-1 (SEQ ID NO: 25) and the encoded amino acid sequence (SEQ ID NO: 26) are set forth in the Sequence Listings. Although further descriptions are made with reference to the BMP- 12 sequence of SEQ ID NO: 1 and 2, it will be recognized that the invention includes similar modifications and

improvements which may be made to other BMP- 12 related sequences, such as the VL-1 sequence shown in SEQ ID NO: 25 and 26.
The sequence of BMP- 12 shown in SEQ ID NO. 1 includes the entire mature sequence and approximately 190 amino acids of the propeptide. The coding sequence of the mature human BMP- 12 protein appears to begin at nucleotide #496 or #571 and continues through nucleotide #882 of SEQ ID NO: 1. The first cysteine in the seven cysteine structure characteristic of TGF-0 proteins begins at nucleotide #577. The last cysteine ends at #879. Thus, it is expected that DNA sequences encoding active BMP- 12 species will comprise nucleotides #577 to #879 of SEQ ID NO: l .
It is expected that BMP- 12, as expressed by mammalian cells such as CHO cells, exists as a heterogeneous population of active species of BMP- 12 protein with varying N-termini. It is expected that all active species will contain the amino acid sequence beginning with the cysteine residue at amino acid #3 of SEQ ID NO: 2 and continue through at least the cysteine residue at amino acid 103 or until the stop codon after amino acid 104. Other active species contain additional amino acid sequence in the N-terminal direction. As described further herein, the N-termini of active species produced by mammalian cells are expected to begin after the occurrence of a consensus cleavage site, encoding a peptide sequence Arg-X-X-Arg. Thus, it is expected that DNA sequences encoding active BMP- 12 proteins will have a nucleotide sequence comprising the nucleotide sequence beginning at any of nucleotides #196, 199, 208, 217, 361, 388, 493, 496 or 571 to nucleotide #879 or 882 of SEQ ID NO: 1.
The N-terminus of one active species of human BMP- 12 has been experimentally determined by expression in E. coli to be as follows: [M]SRXSRKPLHVDF, wherein X designates an amino acid residue with no clear signal, which is consistent with a cysteine residue at that location. Thus, it appears that the N-terminus of this species of BMP- 12 is at amino acid #1 of SEQ ID NO: 1 , and a DNA sequence encoding said species of BMP- 12 would start at nucleotide #571 of SEQ ID NO:l. The apparent molecular weight of this species of human BMP-12 dimer was determined by SDS-PAGE to be approximately 20-22 kd on a

Novex 16% tricine gel. The human BMP-12 protein exists as a clear, colorless solution in 0.1 % trifluoroacetic acid.
As described earlier, BMP- 12 related proteins are a subset of the BMP/TGF- 0/Vg-l family of proteins, including BMP- 12 and VL-1, which can be defined as tendon/ligament-like tissue inducing proteins encoded by DNA sequences which can be cloned and identified, e.g., using PCR, using BMP- 12 specific primers, such as primers #6 and #7 described below, with reduced stringency conditions. It is preferred that DNA sequences of the present invention share at least about 80% homology at the amino acid level from amino acids with the DNA encoding amino acids #3 to #103 of SEQ ID NO: l. For the purposes of the present invention, the term BMP- 12 related proteins does not include the human MP52 protein. Using the sequence information of SEQ ID NO: l and SEQ ID NO: 3, and the comparison provided in Figure 1 , it is within the skill of the art to design primers to the BMP- 12 sequence which will allow for the cloning of genes encoding BMP- 12 related proteins.
One example of the BMP-12-related proteins of the present invention is VL-1 , presently referred to as BMP- 13. The sequence of the full mature BMP- 13 sequence and at least a part of the propeptide of BMP- 13 is given in SEQ ID NO: 25. Like BMP-12, it is expected that BMP-13, as expressed by mammalian cells such as CHO cells, exists as a heterogeneous population of active species of BMP- 13 protein with varying N-termini. It is expected that all active species will contain the amino acid sequence beginning with the cysteine residue at amino acid #19 of SEQ ID NO: 26 and continue through at least the cysteine residue at amino acid 119 or until the stop codon after amino acid 120. Other active species contain additional amino acid sequence in the N-terminal direction. As described further herein, the N-termini of active species produced by mammalian cells are expected to begin after the occurrence of a consensus cleavage site, encoding a peptide sequence Arg-X-X-Arg. Thus, it is expected that DNA sequences encoding active BMP- 13 proteins will have a nucleotide sequence comprising the nucleotide sequence beginning at any of nucleotides #410, 458, 602, 605 or 659, to nucleotide #961 or 964 of SEQ ID NO:25.

In order to produce the purified tendon/ligament-like tissue inducing proteins useful for the present invention, a method is employed comprising culturing a host cell transformed with a DNA sequence comprising a suitable coding sequence, particularly the DNA coding sequence from nucleotide #496, #571 or # 577 to #879 or #882 of SEQ ID NO: l; and recovering and purifying from the culture medium a protein which contains the amino acid sequence or a substantially homologous sequence as represented by amino acids #-25, #1 or #3 to #103 or #104 of SEQ ID NO:2. In another embodiment, the method employed comprises culturing a host cell transformed with a DNA sequence comprising a suitable coding sequence, particularly the DNA coding sequence from nucleotide #605 or # 659 to #961 or #964 of SEQ ID NO: 25; and recovering and purifying from the culture medium a protein which contains the amino acid sequence or a substantially homologous sequence as represented by amino acids #1 or #19 to #119 or #120 of SEQ ID NO:26. The human MP52 DNA is described in WO93/16099, the disclosure of which is incorporated herein by reference. However, this document does not disclose the ability of the protein to form tendon/ligament-like tissue, or its use in compositions for induction of tendon/ligament-like tissue. Human MP52 was originally isolated using PvNA from human embryo tissue. The human MP52 nucleotide sequence (SEQ ID NO:3) and the encoded amino acid sequences (SEQ ID NO:4) are set forth in the Sequence Listings herein. The MP52 protein appears to begin at nucleotide #845 of SEQ ID NO:3 and continues through nucleotide #1204 of SEQ ID NO:3. The first cysteine of the seven cysteine structure characteristic of TGF-3 proteins begins at nucleotide #899. The last cysteine ends at #1201. Other active species of MP52 protein may have additional nucleotides at the N-terminal direction from nucleotide #845 of SEQ ID NO:3.
Purified human MP52 proteins of the present invention may be produced by culturing a host cell transformed with a DNA sequence comprising the DNA coding sequence of SEQ ID NO: 3 from nucleotide #845 to #1204, and recovering and purifying from the culture medium a protein which contains the amino acid sequence or a substantially homologous sequence as represented by amino acids #1 to #120 of SEQ ID NO:4. It is also expected that the amino acid sequence from amino acids
/ o

#17 or #19 to #119 or #120 of SEQ ID NO:4 will retain activity. Thus, the DNA sequence from nucleotides #845, #893 or #899 to #1201 or #1204 are expected to encode active proteins.
For expression of the protein in mammalian host cells, the host cell is transformed with a coding sequence encoding a propeptide suitable for the secretion of proteins by the host cell is linked in proper reading frame to the coding sequence for the mature protein. For example, see United States Patent 5, 168,050, the disclosure of which is hereby incorporated by reference, in which a DNA encoding a precursor portion of a mammalian protein other than BMP-2 is fused to the DNA encoding a mature BMP-2 protein. Thus, the present invention includes chimeric DNA molecules comprising a DNA sequence encoding a propeptide from a member of the TGF-0 superfamily of proteins, is linked in correct reading frame to a DNA sequence encoding a tendon/ligament-like tissue inducing polypeptide. The term «chimeric» is used to signify that the propeptide originates from a different polypeptide than the encoded mature polypeptide. Of course, the host cell may be transformed with a DNA sequence coding sequence encoding the native propeptide linked in correct reading frame to a coding sequence encoding the mature protein shown in SEQ ID NO:2, SEQ ID NO:4, or SEQ ID NO:26. The full sequence of the native propeptide may be determined through methods known in the art using the sequences disclosed in SEQ ID NO:l, SEQ ID NO: 3, or SEQ ID NO: 25 to design a suitable probe for identifying and isolating the entire clone.
The present invention also encompasses the novel DNA sequences, free of association with DNA sequences encoding other proteinaceous materials, and coding for expression of tendon/ligament-like tissue inducing proteins. These DNA sequences include those depicted in SEQ ID NO:l in a 5′ to 3′ direction and those sequences which hybridize thereto under stringent hybridization conditions [for example, 0.1X SSC, 0.1% SDS at 65 °C; see, T. Maniatis et al, Molecular Cloning (A Laboratory Manual). Cold Spring Harbor Laboratory (1982), pages 387 to 389] and encode a protein having tendon/ligament-like tissue inducing activity. Similarly, DNA sequences which code for proteins coded for by the sequences of SEQ ID NO:l or SEQ ID NO:25, or proteins which comprise the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 26, but which differ in codon

sequence due to the degeneracies of the genetic code or allelic variations (naturally- occurring base changes in the species population which may or may not result in an amino acid change) also encode the tendon/ligament-like tissue inducing proteins described herein. Variations in the DNA sequences of SEQ ID NO: l or SEQ ID NO: 25 which are caused by point mutations or by induced modifications (including insertion, deletion, and substitution) to enhance the activity, half-life or production of the polypeptides encoded are also encompassed in the invention.
Another aspect of the present invention provides a novel method for producing tendon/ligament-like tissue inducing proteins. The method of the present invention involves culturing a suitable cell line, which has been transformed with a DNA sequence encoding a protein of the invention, under the control of known regulatory sequences. The transformed host cells are cultured and the proteins recovered and purified from the culture medium. The purified proteins are substantially free from other proteins with which they are co-produced as well as from other contaminants.
Suitable cells or cell lines may be mammalian cells, such as Chinese hamster ovary cells (CHO). As described above, expression of protein in mammalian cells requires an appropriate propeptide to assure secretion of the protein. The selection of suitable mammalian host cells and methods for transformation, culture, amplification, screening, product production and purification are known in the art. See, e.g., Gething and Sambrook, Nature. 293:620-625 (1981), or alternatively, Kaufman et al, Mol. Cell. Biol.. 5(7): 1750-1759 (1985) or Howley et al, U.S. Patent 4,419,446. Another suitable mammalian cell line, which is described in the accompanying examples, is the monkey COS-1 cell line. The mammalian cell CV-1 may also be suitable.
Bacterial cells may also be suitable hosts. For example, the various strains of E. coli (e.g., HBlOl, MC1061) are well-known as host cells in the field of biotechnology. Various strains of B. subtilis. Pseudomonas. other bacilli and the like may also be employed in this method. For expression of the protein in bacterial cells, DNA encoding a propeptide is not necessary.
Bacterial expression of mammalian proteins, including members of the TGF-β family is known to produce the proteins in a non-glycosylated form, and in the form
I S-

of insoluble pellets, known as inclusion bodies. Techniques have been described in the art for solubilizing these inclusion bodies, denaturing the protein using a chaotropic agent, and refolding the protein sufficiently correctly to allow for their production in a soluble form. For example, see EP 0433225, the disclosure of which is hereby incorporated by reference.
Alternatively, methods have been devised which circumvent inclusion body formation, such as expression of gene fusion proteins, wherein the desired protein is expressed as a fusion protein with a fusion partner. The fusion protein is later subjected to cleavage to produce the desired protein. One example of such a gene fusion expression system for R coli is based on use of the R. coli thioredoxin gene as a fusion partner, LaVallie et al. , Bio/Technology. 11 : 187-193 (1993), the disclosure of which is hereby incorporated by reference.
Many strains of yeast cells known to those skilled in the art may also be available as host cells for expression of the polypeptides of the present invention. Additionally, where desired, insect cells may be utilized as host cells in the method of the present invention. See, e.g. Miller et al, Genetic Engineering. 8:277-298 (Plenum Press 1986) and references cited therein.
Another aspect of the present invention provides vectors for use in the method of expression of these tendon/ligament-like tissue inducing proteins. Preferably the vectors contain the full novel DNA sequences described above which encode the novel factors of the invention. Additionally, the vectors contain appropriate expression control sequences permitting expression of the protein sequences. Alternatively, vectors incorporating modified sequences as described above are also embodiments of the present invention. Additionally, the sequence of SEQ ID NO: 1 or SEQ ID NO: 3 or SEQ ID NO: 25 could be manipulated to express a mature protein by deleting propeptide sequences and replacing them with sequences encoding the complete propeptides of BMP proteins or members of the TGF-/3 superfamily. Thus, the present invention includes chimeric DNA molecules encoding a propeptide from a member of the TGF-/3 superfamily linked in correct reading frame to a DNA sequence encoding a protein having the amino acid sequence of SEQ ID NO: 2 or
SEQ ID NO: 4 or SEQ ID NO: 26. The vectors may be employed in the method of transforming cell lines and contain selected regulatory sequences in operative
/-3

association with the DNA coding sequences of the invention which are capable of directing the replication and expression thereof in selected host cells. Regulatory sequences for such vectors are known to those skilled in the art and may be selected depending upon the host cells. Such selection is routine and does not form part of the present invention.
A protein of the present invention, which induces tendon/ligament-like tissue or other tissue formation in circumstances where such tissue is not normally formed, has application in the healing of tendon or ligament tears, deformities and other tendon or ligament defects in humans and other animals. Such a preparation employing a tendon/ligament-like tissue inducing protein may have prophylactic use in preventing damage to tendon or ligament tissue, as well as use in the improved fixation of tendon or ligament to bone or other tissues, and in repairing defects to tendon or ligament tissue. De novo tendon/ligament-like tissue formation induced by a composition of the present invention contributes to the repair of congenital, trauma induced, or other tendon or ligament defects of other origin, and is also useful in cosmetic plastic surgery for attachment or repair of tendons or ligaments. The compositions of the invention may also be useful in the treatment of tendinitis, caφal tunnel syndrome and other tendon or ligament defects. The compositions of the present invention can also be used in other indications wherein it is desirable to heal or regenerate tendon and/or ligament tissue. Such indications include, without limitation, regeneration or repair of injuries to the periodontal ligament, such as occurs in tendonitis, and regeneration or repair of the tendon-to-bone attachment. The compositions of the present invention may provide an environment to attract tendon- or ligament-forming cells, stimulate growth of tendon- or ligament-forming cells or induce differentiation of progenitors of tendon- or ligament-forming cells.
The BMP- 12 related proteins may be recovered from the culture medium and purified by isolating them from other proteinaceous materials from which they are co-produced and from other contaminants present. The proteins of the present invention are capable of inducing the formation of tendon/ligament-like tissue. These proteins may be further characterized by the ability to demonstrate tendon/ligament-like tissue formation activity in the rat ectopic implant assay

described below. It is contemplated that these proteins may have ability to induce the formation of other types of tissue, such as ligaments, as well.
The tendon/ligament-like tissue inducing proteins provided herein also include factors encoded by the sequences similar to those of SEQ ID NO: l or SEQ ID NO: 25, but into which modifications are naturally provided (e.g. allelic variations in the nucleotide sequence which may result in amino acid changes in the polypeptide) or deliberately engineered. For example, synthetic polypeptides may wholly or partially duplicate continuous sequences of the amino acid residues of SEQ ID NO: 2. These sequences, by virtue of sharing primary, secondary, or tertiary structural and conformational characteristics with tendon/ligament-like tissue growth factor polypeptides of SEQ ID NO: 2 may possess tendon/ligament-like or other tissue growth factor biological properties in common therewith. Thus, they may be employed as biologically active substitutes for naturally-occurring tendon/ligament- like tissue inducing polypeptides in therapeutic compositions and processes.
Other specific mutations of the sequences of tendon/ligament-like tissue inducing proteins described herein involve modifications of glycosylation sites. These modifications may involve O-linked or N-linked glycosylation sites. For instance, the absence of glycosylation or only partial glycosylation results from amino acid substitution or deletion at asparagine-linked glycosylation recognition sites. The asparagine-linked glycosylation recognition sites comprise tripeptide sequences which are specifically recognized by appropriate cellular glycosylation enzymes. These tripeptide sequences may be asparagine-X-threonine, asparagine-X- serine or asparagine-X-cysteine, where X is usually any amino acid except proline. A variety of amino acid substitutions or deletions at one or both of the first or third amino acid positions of a glycosylation recognition site (and/or amino acid deletion at the second position) results in non-glycosylation at the modified tripeptide sequence. Additionally, bacterial expression of protein will also result in production of a non-glycosylated protein, even if the glycosylation sites are left unmodified.
The compositions of the present invention comprise a purified BMP- 12 related protein which may be produced by culturing a cell transformed with the DNA sequence of SEQ ID NO: 1 or SEQ ID NO: 25 and recovering and purifying protein having the amino acid sequence of SEQ ID NO: 2 or SEQ ID NO: 26 from the culture

medium. The purified expressed protein is substantially free from other proteinaceous materials with which it is co-produced, as well as from other contaminants. The recovered purified protein is contemplated to exhibit tendon/ligament-like tissue formation activity, and other tissue growth activity, such as ligament regeneration. The proteins of the invention may be further characterized by the ability to demonstrate tendon/ligament-like tissue formation activity in the rat assay described below.
The compositions for inducing tendon/ligament-like tissue formation of the present invention may comprise an effective amount of a tendon/ligament-like tissue inducing protein, wherein said protein comprises the amino acid sequence of SEQ ID NO:2, preferably amino acids #-25, #1 or #3 to #103 or #104 of SEQ ID NO:2; or amino acids #1 or #19 to #120 of SEQ ID NO: 26; as well as mutants and/or variants of SEQ ID NO:2 or SEQ ID NO:26, which exhibit the ability to form tendon and/or ligament like tissue.
Compositions of the present invention may further comprise additional proteins, such as additional members of the TGF-β superfamily of proteins, such as activins. Another aspect of the invention provides pharmaceutical compositions containing a therapeutically effective amount of a tendon/ligament-inducing protein, such as BMP- 12 or VL-1 , in a pharmaceutically acceptable vehicle or carrier. These compositions may be used to induce the formation of tendon/ligament-like tissue or other tissue. It is contemplated that such compositions may also be used for tendon and ligament repair, wound healing and other tissue repair, such as skin repair. It is further contemplated that proteins of the invention may increase neuronal survival and therefore be useful in transplantation and treatment of conditions exhibiting a decrease in neuronal survival. Compositions of the invention may further include at least one other therapeutically useful agent, such as the BMP proteins BMP-1,
BMP-2, BMP-3, BMP-4, BMP-5, BMP-6 and BMP-7, disclosed for instance in
United States Patents 5,108,922; 5,013,649; 5,116,738; 5,106,748; 5,187,076; and
5,141,905; BMP-8, disclosed in PCT publication WO91/ 18098; BMP-9, disclosed in PCT publication WO93/00432; and BMP-10 or BMP-11, disclosed in co-pending patent applications, serial number 08/061,695 and 08/061,464, filed on May 12,
/ &>

1993. The disclosure of the above documents are hereby incoφorated by reference herein.
The compositions of the invention may comprise, in addition to a tendon/ligament-inducing protein such as BMP-12 or VL-1 (BMP-13), other therapeutically useful agents including MP52, epidermal growth factor (EGF), fibroblast growth factor (FGF), platelet derived growth factor (PDGF), transforming growth factors (TGF-α and TGF-/3), and fibroblast growth factor-4 (FGF-4), parathyroid hormone (PTH), leukemia inhibitory factor (LIF/HILDA/DIA), insulin¬ like growth factors (IGF-I and IGF-II). Portions of these agents may also be used in compositions of the present invention. For example, a composition comprising both BMP-2 and BMP- 12 implanted together gives rise to both bone and tendon/ligament-like tissue. Such a composition may be useful for treating defects of the embryonic joint where tendon, ligaments, and bone form simultaneously at contiguous anatomical locations, and may be useful for regenerating tissue at the site of tendon attachment to bone. It is contemplated that the compositions of the invention may also be used in wound healing, such as skin healing and related tissue repair. The types of wounds include, but are not limited to burns, incisions and ulcers. (See, e.g. PCT Publication WO84/01106 for discussion of wound healing and related tissue repair).
It is expected that the proteins of the invention may act in concert with or perhaps synergistically with other related proteins and growth factors. Further therapeutic methods and compositions of the invention therefore comprise a therapeutic amount of at least one protein of the invention with a therapeutic amount of at least one of the BMP proteins described above. Such compositions may comprise separate molecules of the BMP proteins or heteromolecules comprised of different BMP moieties. For example, a method and composition of the invention may comprise a disulfide linked dimer comprising a BMP-12 related protein subunit and a subunit from one of the «BMP» proteins described above. Thus, the present invention includes compositions comprising a purified BMP- 12 related polypeptide which is a heterodimer wherein one subunit comprises the amino acid sequence from amino acid #1 to amino acid #104 of SEQ ID NO:2, and one subunit comprises an amino acid sequence for a bone morphogenetic protein selected from the group

consisting of BMP-1, BMP-2, BMP-3, BMP-4, BMP-5, BMP-6, BMP-7, BMP-8, BMP-9, BMP- 10 and BMP-11. A further embodiment may comprise a heterodimer of disulfide bonded tendon/ligament-like tissue inducing moieties such as BMP-12, VL-1 (BMP- 13) or MP52. For example the heterodimer may comprise one subunit comprising an amino acid sequence from #1 to # 104 of SEQ ID NO: 2 and the other subunit may comprise an amino acid sequence from #1 to #120 of SEQ ID NO:4 or #1 to #120 of SEQ ID NO: 26. Further, compositions of the present invention may be combined with other agents beneficial to the treatment of the defect, wound, or tissue in question.
The preparation and formulation of such physiologically acceptable protein compositions, having due regard to pH, isotonicity, stability and the like, is within the skill of the art. The therapeutic compositions are also presently valuable for veterinary applications due to the lack of species specificity in TGF-β proteins. Particularly domestic animals and thoroughbred horses in addition to humans are desired patients for such treatment with the compositions of the present invention.
The therapeutic method includes administering the composition topically, systemically, or locally as an implant or device. When administered, the therapeutic composition for use in this invention is, of course, in a pyrogen-free, physiologically acceptable form. Further, the composition may desirably be encapsulated or injected in a viscous form for delivery to the site of tissue damage. Topical administration may be suitable for wound healing and tissue repair. Therapeutically useful agents other than the proteins which may also optionally be included in the composition as described above, may alternatively or additionally, be administered simultaneously or sequentially with the composition in the methods of the invention.
The compositions may also include an appropriate matrix and/or sequestering agent as a carrier. For instance, the matrix may support the composition or provide a surface for tendon ligament-like tissue formation and/or other tissue formation. The matrix may provide slow release of the protein and/or the appropriate environment for presentation thereof. The sequestering agent may be a substance which aids in ease of administration through injection or other means, or may slow the migration of protein from the site of application.
/r

The choice of a carrier material is based on biocompatibility, biodegradability, mechanical properties, cosmetic appearance and interface properties. The particular application of the compositions will define the appropriate formulation. Potential matrices for the compositions may be biodegradable and chemically defined. Further matrices are comprised of pure proteins or extracellular matrix components. Other potential matrices are nonbiodegradable and chemically defined. Preferred matrices include collagen-based materials, such as Helistat* sponge (Integra LifeSciences, Plainsboro, N.J.), or collagen in an injectable form, as well as sequestering agents, which may also be biodegradable, and which may include alkylcellulosic materials.
Another preferred class of carrier are porous particulate polymer matrices, including polymers of poly (lactic acid), poly(glycolic acid) and copolymers of lactic acid and gly colic acid. These matrices may also include a sequestering agent. Suitable polymer matrices are described, for example, in WO 93/00050, the disclosure of which is incoφorated herein by reference.
A preferred family of sequestering agents is cellulosic materials such as alkylcelluloses (including hydroxyalkylcelluloses), including methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl- methylcellulose, and carboxymethylcellulose, the most preferred being cationic salts of carboxymethylcellulose (CMC). Other preferred sequestering agents include hyaluronic acid, sodium alginate, poly(ethylene gly col), polyoxyethylene oxide, carboxy vinyl polymer and poly(vinyl alcohol). The amount of sequestering agent useful herein is 0.5-20 wt% , preferably 1-10 wt% based on total formulation weight, which represents the amount necessary to prevent desorbtion of the protein from the polymer matrix and to provide appropriate handling of the composition, yet not so much that the progenitor cells are prevented from infiltrating the matrix, thereby providing the protein the opportunity to assist the activity of the progenitor cells.
Additional optional components useful in the practice of the subject application include, e.g. cryogenic protectors such as mannitol, sucrose, lactose, glucose, or glycine (to protect the protein from degradation during lyophilization), antimicrobial preservatives such as methyl and propyl parabens and benzyl alcohol;
‘ ?

antioxidants such as EDTA, citrate and BHT (butylated hydroxy toluene); and surfactants such as poly(sorbates) and poly(oxyethylenes); etc.
As described above, the compositions of the invention may be employed in methods for treating a number of tendon defects, such as the regeneration of tendon ligament-like tissue in areas of tendon or ligament damage, to assist in repair of tears of tendon tissue, ligaments, and various other types of tissue defects or wounds. These methods, according to the invention, entail administering to a patient needing such tendon/ligament-like tissue or other tissue repair, a composition comprising an effective amount of a tendon/ligament-like tissue inducing protein, such as described in SEQ ID NO:2, SEQ ID NO:4 and/or SEQ ID NO:26. These methods may also entail the administration of a tendon/ligament-like tissue inducing protein in conjunction with at least one of the BMP proteins described above.
In another embodiment, the methods may entail administration of a heterodimeric protein in which one of the monomers is a tendon ligament-like tissue inducing polypeptide, such as BMP-12, VL-1 (BMP-13) or MP52, and the second monomer is a member of the TGF- 3 superfamily of growth factors. In addition, these methods may also include the administration of a tendon/ligament-like tissue inducing protein with other growth factors including EGF, FGF, TGF-α, TGF-3, and IGF.
Thus, a further aspect of the invention is a therapeutic method and composition for repairing tendon/ligament-like tissue, for repairing tendon or ligament as well as treating tendinitis and other conditions related to tendon or ligament defects. Such compositions comprise a therapeutically effective amount of one or more tendon/ligament-like tissue inducing proteins, such as BMP- 12, a BMP-12 related protein, or MP52, in admixture with a pharmaceutically acceptable vehicle, carrier or matrix.
The dosage regimen will be determined by the attending physician considering various factors which.modify the action of the composition, e.g., amount of tendon or ligament tissue desired to be formed, the site of tendon or ligament damage, the condition of the damaged tendon or ligament, the size of a wound, type of damaged tissue, the patient’s age, sex, and diet, the severity of any infection, time of administration and other clinical factors. The dosage may vary with the type of

matrix used in the reconstitution and the types of additional proteins in the composition. The addition of other known growth factors, such as IGF-I (insulin like growth factor I), to the final composition, may also affect the dosage.
Progress can be monitored by periodic assessment of tendon/ligament-like tissue formation, or tendon or ligament growth and/or repair. The progress can be monitored by methods known in the art, for example, X-rays, arthroscopy, histomoφhometric determinations and tetracycline labeling.
The following examples illustrate practice of the present invention in recovering and characterizing human tendon/ligament-like tissue inducing protein and employing them to recover the other tendon/ligament-like tissue inducing proteins, obtaining the human proteins, expressing the proteins via recombinant techniques, and demonstration of the ability of the compositions of the present invention to form tendon/ligament-like tissue in an in vivo model. Although the examples demonstrate the invention with respect to BMP- 12, with minor modifications within the skill of the art, the same results are believed to be attainable with MP52 and VL-1. EXAMPLE 1 Isolation of DNA
DNA sequences encoding BMP- 12 and BMP- 12 related proteins may be isolated by various techniques known to those skilled in the art. As described below, oligonucleotide primers may be designed on the basis of amino acid sequences present in other BMP proteins, Vg-1 related proteins and other proteins of the TGF- β superfamily. Regions containing amino acid sequences which are highly conserved within the BMP family of proteins and within other members of the TGF-β superfamily of proteins can be identified and consensus amino acid sequences of these highly conserved regions can be constructed based on the similarity of the corresponding regions of individual BMP/TGF-β/ Vg- 1 proteins . An example of such a consensus amino acid sequence is indicated below. Consensus amino acid sequence (1):
Tφ-Gln/Asn-Asp-Tφ-Ile-Val/Ile-Ala (SEQ ID NO: 16) Where X/Y indicates that either amino acid residue may appear at that position.
3/

The following oligonucleotide is designed on the basis of the above identified consensus amino acid sequence (1):
#1 : CGGATCCTGGVANGAYTGGATHRTNGC (SEQ ID NO: 17)
This oligonucleotide sequence is synthesized on an automated DNA synthesizer. The standard nucleotide symbols in the above identified oligonucleotide primer are as follows: A,adenosine; C,cytosine; G,guanine; T,thymine; N,adenosine or cytosine or guanine or thymine; R,adenosine or cytosine; Y,cytosine or thymine; H,adenosine or cytosine or thymine; V,adenosine or cytosine or guanine; D,adenosine or guanine or thymine.
The first seven nucleotides of oligonucleotide #1 (underlined) contain the recognition sequence for the restriction endonuclease BamHI in order to facilitate the manipulation of a specifically amplified DNA sequence encoding the BMP- 12 protein and are thus not derived from the consensus amino acid sequence (1) presented above.
A second consensus amino acid sequence is derived from another highly conserved region of BMP/TGF-3/Vg-l proteins as described below:
His-Ala-Ile-Val/Leu-Gln-Thr (SEQ ID NO: 18)
The following oligonucleotide is designed on the basis of the above identified consensus amino acid sequence (2):
#2: TTTCTAGAARNGTYTGNACDATNGCRTG (SEQ ID NO: 19)
This oligonucleotide sequence is synthesized on an automated DNA synthesizer. The same nucleotide symbols are used as described above.
The first seven nucleotides of oligonucleotide #1 (underlined) contain the recognition sequence for the restriction endonuclease Xbal in order to facilitate the manipulation of a specifically amplified DNA sequence encoding the BMP- 12 protein and are thus not derived from the consensus amino acid sequence (2) presented above.
It is contemplated that the BMP- 12 protein of the invention and other BMP/TGF-0/Vg-l related proteins may contain amino acid sequences similar to the consensus amino acid sequences described above and that the location of those sequences within a BMP- 12 protein or other novel related proteins would correspond to the relative locations in the proteins from which they were derived. It is further 3-

contemplated that this positional information derived from the structure of other BMP/TGF-/3/Vg-l proteins and the oligonucleotide sequences #1 and #2 which have been derived from consensus amino acid sequences (1) and (2), respectively, could be utilized to specifically amplify DNA sequences encoding the corresponding amino acids of a BMP- 12 protein or other BMP/TGF-0/Vg-l related proteins.
Based on the knowledge of the gene structures of BMP/TGF-β/Vg-1 proteins it is further contemplated that human genomic DNA can be used as a template to perform specific amplification reactions which would result in the identification of BMP-12 BMP/TGF-/3/Vg-l (BMP-12 related protein) encoding sequences. Such specific amplification reactions of a human genomic DNA template could be initiated with the use of oligonucleotide primers #1 and #2 described earlier. Oligonucleotides #1 and #2 identified above are utilized as primers to allow the specific amplification of a specific nucleotide sequence from human genomic DNA. The amplification reaction is performed as follows:
Human genomic DNA (source: peripheral blood lymphocytes), provided by Ken Jacobs of Genetics Institute, is sheared by repeated passage through a 25 gauge needle, denatured at 100°C for 5 minutes and then chilled on ice before adding to a reaction mixture containing 200 μM each deoxy nucleotide triphosphates (dATP, dGTP, dCTP and dTTP), 10 mM Tris-HCl pH 8.3, 50 mM KC1, 1.5 mM MgCl2, 0.001 % gelatin, 1.25 units Taq DNA polymerase, 100 pM oligonucleotide #1 and 100 pM oligonucleotide #2. This reaction mixture is incubated at 94°C for two minutes and then subjected to thermal cycling in the following manner: 1 minute at 94°C, 1 minute at 40°C, 1 minute at 72°C for three cycles; then 1 minute at 94°C, 1 minute at 55°C, 1 minute at 72°C for thirty-seven cycles, followed by a 10 minute incubation at 72°C.
The DNA which is specifically amplified by this reaction is ethanol precipitated, digested with the restriction endonucleases BamHI and Xbal and subjected to agarose gel electrophoresis. A region of the gel, corresponding to the predicted size of the BMP- 12 or other BMP/TGF-3/Vg-l encoding DNA fragment, is excised and the specifically amplified DNA fragments contained therein are electroeluted and subcloned into the plasmid vector pGEM-3 between the Xbal and
BamHI sites of the polylinker. DNA sequence analysis of one of the resulting BMP-

12 related subclones indicates the specifically amplified DNA sequence product contained therein encodes a portion of the BMP-12 protein of the invention.
The DNA sequence (SEQ ID NO: 5) and derived amino acid sequence (SEQ ID NO: 6) of this specifically amplified DNA fragment of BMP- 12 are shown in the SEQUENCE Listings.
Nucleotides #l-#26 of SEQ ID NO: 5 comprise a portion of oligonucleotide #1 and nucleotides #103 – #128 comprise a portion of the reverse compliment of oligonucleotide #2 utilized to perform the specific amplification reaction. Due to the function of oligonucleotides #1 and #2 in initiating the amplification reaction, they may not correspond exactly to the actual sequence encoding a BMP- 12 protein and are therefore not translated in the corresponding amino acid derivation (SEQ ID NO:6).
DNA sequence analysis of another subclone indicates that the specifically amplified DNA product contained therein encodes a portion of another BMP/TGF- β/Vg-1 (BMP- 12 related) protein of the invention named VL-1.
The DNA sequence (SEQ ID NO: 7) and derived amino acid sequence (SEQ ID NO: 8) of this specifically amplified DNA fragment are shown in the Sequence Listings.
Nucleotides #1 – #26 of SEQ ID NO: 7 comprise a portion of oligonucleotide #1 and nucleotides #103 – #128 comprise a portion of the reverse compliment of oligonucleotide #2 utilized to perform the specific amplification reaction. Due to the function of oligonucleotides #1 and #2 in initiating the amplification reaction, they may not correspond exactly to the actual sequence encoding a VL-1 protein of the invention and are therefore not translated in the corresponding amino acid derivation (SEQ ID NO: 8).
The following oligonucleotide probe is designed on the basis of the specifically amplified BMP- 12 human DNA sequence set forth above (SEQ ID NO:5) and synthesized on an automated DNA synthesizer: #3: CCACTGCGAGGGCCTTTGCGACTTCCCTTTGCGTTCGCAC (SEQ ID NO:20)
This oligonucleotide probe is radioactively labeled with 32P and employed to screen a human genomic library constructed in the vector λFIX (Stratagene catalog
•9 V

#944201). 500,000 recombinants of the human genomic library are plated at a density of approximately 10,000 recombinants per plate on 50 plates. Duplicate nitrocellulose replicas of the recombinant bacteriophage plaques and hybridized to oligonucleotide probe #3 in standard hybridization buffer (SHB = 5X SSC, 0.1 %
SDS, 5X Denhardt’s, 100 μg/ml salmon sperm DNA) at 65°C overnight. The following day the radioactively labelled oligonucleotide containing hybridization solution is removed an the filters are washed with 0.2X SSC, 0.1 % SDS at 65°C.
A single positively hybridizing recombinant is identified and plaque purified. This plaque purified recombinant bacteriophage clone which hybridizes to the BMP- 12 oligonucleotide probe #3 is designated λHuG-48. A bacteriophage plate stock is made and bacteriophage DNA is isolated from the λHuG-48 human genomic clone.
The bacteriophage λHuG-48 has been deposited with the American Type Culture
Collection, 12301 Parklawn Drive, Rockville, MD «ATCC» under the accession
#75625 on December 7, 1993. This deposit meets the requirements of the Budapest
Treaty of the International Recognition of the Deposit of Microorganisms for the
Puφose of Patent Procedure and Regulations thereunder. The oligonucleotide hybridizing region of this recombinant, λHuG-48, is localized to a 3.2 kb BamHI fragment. This fragment is subcloned into a plasmid vector (pGEM-3) and DNA sequence analysis is performed. This plasmid subclone is designated PCR1-1#2 and has been deposited with the American Type Culture Collection, 12301 Parklawn
Drive, Rockville, MD «ATCC» under the accession #69517 on December 7, 1993.
This deposit meets the requirements of the Budapest Treaty of the International
Recognition of the Deposit of Microorganisms for the Puφose of Patent Procedure and Regulations thereunder. The partial DNA sequence (SEQ ID NO: 1) and derived amino acid sequence (SEQ ID NO: 2) of the 3.2 kb DNA insert of the plasmid subclone PCR1-1#2, derived from clone λHuG-48, are shown in the
Sequence Listings.
It should be noted that nucleotides #639 – #714 of SEQ ID NO: 1 correspond to nucleotides #27 – #102 of the specifically amplified BMP-12 encoding DNA fragment set forth in SEQ ID NO: 5 thus confirming that the human genomic bacteriophage clone λHuG-48 and derivative subclone PCR1-1#2 encode at least a portion of the BMP- 12 protein of the invention. The nucleotide sequence of a
3JT

portion of the 3.2 kb BamHI insert of the plasmid PCR1-1#2 contains an open reading frame of at least 882 base pairs, as defined by nucleotides #l-#882 of SEQ ID NO: l. This open reading frame encodes at least 294 amino acids of the human BMP- 12 protein of the invention. The encoded 294 amino acid human BMP- 12 protein includes the full mature human BMP- 12 protein (amino acids #1-#104 of SEQ ID NO: 2), as well as the C-terminal portion of the propeptide region of the primary translation product (amino acid #-190 to #-1 of SEQ ID NO: 2).
Additional DNA sequence of the 3.2 kb BamHI insert of the plasmid PCR1- 1#2 set forth in SEQ ID NO: 33 demonstrates the presence of an 1164 bp open reading frame, as defined by nucleotides #138 through #1301 of SEQ ID NO:33. [NOTE that all the sequence disclosed in SEQ ID NO: 1 is contained within SEQ ID NO: 33]. As this sequence is derived from a genomic clone it is difficult to determine the boundary between the 5′ extent of coding sequence and the 3′ limit of intervening sequence (intron/ non-coding sequence).
Based on the knowledge of other BMP proteins and other proteins within the TGF-0 family, it is predicted that the precursor polypeptide would be cleaved at the multibasic sequence Arg-Arg-Gly-Arg in agreement with a proposed consensus proteolytic processing sequence of Arg-X-X-Arg. Cleavage of the BMP- 12 precursor polypeptide is expected to generate a 104 amino acid mature peptide beginning with the amino acid Ser at position #1 of SEQ ID NO:2. The processing of BMP- 12 into the mature form is expected to involve dimerization and removal of the N-terminal region in a manner analogous to the processing of the related protein TGF-0 [Gentry et al. , Molec & Cell. Biol.. 8:4162 (1988); Derynck et al. Nature. 316:701 (1985)].
It is contemplated therefore that the mature active species of BMP- 12 comprises a homodimer of two polypeptide subunits, each subunit comprising amino acids #1 to #104 of SEQ ID NO: 2 with a predicted molecular weight of approximately 12,000 daltons. Further active species are contemplated comprising at least amino acids #3 to #103 of SEQ ID NO:2, thereby including the first and last conserved cysteine residue. As with other members of the TGF-β/BMP family of proteins, the carboxy-terminal portion of the BMP- 12 protein exhibits greater sequence conservation than the more arnino-terminal portion. The percent amino
•aύ*-

acid identity of the human BMP- 12 protein in the cysteine-rich C-terminal domain (amino acids #3 – #104) to the corresponding region of human BMP proteins and other proteins within the TGF-/3 family is as follows: BMP-2, 55%; BMP-3, 43% ; BMP-4, 53%; BMP-5, 49%; BMP-6, 49%; BMP-7, 50%; BMP-8, 57%; BMP-9, 48%; BMP-10, 57%; activin WC (BMP- 11), 38%; Vgl, 46%; GDF-1, 47%; TGF- 01, 36%; TGF-/32, 36%; TGF-/33, 39%; inhibin /3(B), 36%; inhibin /3(A), 41 % .
The human BMP-12 DNA sequence (SEQ ID NO: l), or a portion thereof, can be used as a probe to identify a human cell line or tissue which synthesizes BMP- 12 mRNA. Briefly described, RNA is extracted from a selected cell or tissue source and either electrophoresed on a formaldehyde agarose gel and transferred to nitrocellulose, or reacted with formaldehyde and spotted on nitrocellulose directly. The nitrocellulose is then hybridized to a probe derived from the coding sequence of human BMP- 12.
Alternatively, the human BMP- 12 sequence is used to design oligonucleotide primers which will specifically amplify a portion of the BMP- 12 encoding sequence located in the region between the primers utilized to perform the specific amplification reaction. It is contemplated that these human BMP- 12 derived primers would allow one to specifically amplify corresponding BMP- 12 encoding sequences from mRNA, cDNA or genomic DNA templates. Once a positive source has been identified by one of the above described methods, mRNA is selected by oligo (dT) cellulose chromatography and cDNA is synthesized and cloned in λgtlO or other λ bacteriophage vectors known to those skilled in the art, for example, λZAP by established techniques (Toole et al., supra). It is also possible to perform the oligonucleotide primer directed amplification reaction, described above, directly on a pre-established human cDNA or genomic library which has been cloned into a λ bacteriophage vector. In such cases, a library which yields a specifically amplified DNA product encoding a portion of the human BMP- 12 protein could be screened directly, utilizing the fragment of amplified BMP- 12 encoding DNA as a probe.
Oligonucleotide primers designed on the basis of the DNA sequence of the human BMP- 12 genomic clone λHuG-48 are predicted to allow the specific amplification of human BMP- 12 encoding DNA sequences from pre-established human cDNA libraries which are commercially available (ie. Stratagene, La Jolla,
3 *7

CA or Clontech Laboratories, Inc. , Palo Alto, CA). The following oligonucleotide primer is designed on the basis of nucleotides #571 to #590 of the DNA sequence set forth in SEQ ID NO: l and synthesized on an automated DNA synthesizer:
#4: TGCGGATCCAGCCGCTGCAGCCGCAAGCC (SEQ ID NO:21)
The first nine nucleotides of primer #4 (underlined) comprise the recognition sequence for the restriction endonuclease BamHI which can be used to facilitate the manipulation of a specifically amplified DNA sequence encoding the human BMP- 12 protein of the invention and are thus not derived from the DNA sequence presented in SEQ ID NO: 1.
The following oligonucleotide primer is designed on the basis of nucleotides #866 – #885 of the DNA sequence set forth in SEQ ID NO: l and synthesized on an automated DNA synthesizer:
#5 GACTCTAGACTACCTGCAGCCGCAGGCCT (SEQ ID NO:22)
The first nine nucleotides of primer #5 (underlined) comprise the recognition sequence for the restriction endonuclease Xbal which can be used to facilitate the manipulation of a specifically amplified DNA sequence encoding the human BMP- 12 protein of the invention and are thus not derived from the DNA sequence presented in SEQ ID NO: 1.
The standard nucleotide symbols in the above identified primers are as follows: A, adenine; C, cytosine; G, guanine; T, thymine.
Primers #4 and #5 identified above are utilized as primers to allow the amplification of a specific BMP- 12 encoding nucleotide sequence from pre- established cDNA libraries which may include the following: human fetal brain cDNA/λZAPII (Stratagene catalog #936206), human liver/λUNI-ZAP XR (Stratagene Catalog #937200), human lung/λUNI-ZAP XR (Stratagene catalog #937206), and human fetal spleen/UNI-ZAP XR (Stratagene catalog #937205).
Approximately 1 x 108 pfu (plaque forming units) of λbacteriophage libraries containing human cDNA inserts such as those detailed above are denatured at 95°C for five minutes prior to addition to a reaction mixture containing 200 μM each deoxynucleotide triphosphates (dATP, dGTP, dCTP and dTTP) 10 mM Tris-HCl pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 0.001 % gelatin, 1.25 units Taq DNA polymerase, 100 pM oligonucleotide primer #4 and 100 pM oligonucleotide primer r

#5. The reaction mixture is then subjected to thermal cycling in the following manner: 1 minute at 94°C, 1 minute at 50°C, 1 minute at 72°C for thirty-nine cycles followed by 10 minutes at 72°C.
The DNA which is specifically amplified by this reaction would be expected to generate a BMP- 12 encoding product of approximately 333 base pairs, the internal 315 bp of which correspond to nucleotides #571 to #885 of SEQ ID NO: l and also including 9 bp at each end of the BMP- 12 specific fragment which correspond to the restriction sites defined by nucleotides #1 – #9 of primers #4 and #5. The resulting 333 bp DNA product is digested with the restriction endonucleases BamHI and Xbal, phenol extracted, chloroform extracted and ethanol precipitated.
Alternatively, to ethanol precipitation, buffer exchange and removal of small fragments of DNA resulting from the BamHI/Xbal restriction digest is accomplished by dilution of the digested DNA product in 10 mM Tris-HCl pH 8.0, 1 mM EDTA followed by centrifugation through a Centricon™ 30 microconcentrator (W.R. Grace & Co. , Beverly, MA; Product #4209). The resulting BamHI/Xbal digested amplified DNA product is subcloned into a plasmid vector (ie. pBluescript, pGEM-3 etc.) between the BamHI and Xbal sites of the polylinker region. DNA sequence analysis of the resulting subclones would be required to confirm the integrity of the BMP- 12 encoding insert. Once a positive cDNA source has been identified in this manner, the corresponding cDNA library from which a 333 bp BMP-12 specific sequence was amplified could be screened directly with the 333 bp insert or other BMP- 12 specific probes in order to identify and isolate cDNA clones encoding the full-length BMP- 12 protein of the invention.
Additional methods known to those skilled in the art may be used to isolate other full-length cDNAs encoding human BMP- 12 related proteins, or full length cDNA clones encoding BMP- 12 related proteins of the invention from species other than humans, particularly other mammalian species.
The following examples demonstrate the use of the human BMP- 12 sequence to isolate homologues from BMP- 12 related proteins in a murine genomic DNA ** library.
The DNA sequence which encodes the human BMP- 12 protein of the invention is predicted to be significantly homologous to BMP- 12 and BMP- 12 related a

sequences from species other than humans that it could be utilized to specifically amplify DNA sequences from those other species which would encode the corresponding BMP- 12 related proteins. Specifically, the following oligonucleotides are designed on the basis of the human BMP- 12 sequence (SEQ ID NO: l) and are synthesized on an automated DNA synthesizer:
#6: GCGGATCCAAGGAGCTCGGCTGGGACGA (SEQ ID NO:23)
#7: GGAATTCCCCACCACCATGTCCTCGTAT (SEQ ID NO:24)
The first eight nucleotides of oligonucleotide primers #6 and #7 (underlined) comprise the recognition sequence for the restriction endonucleases BamHI and
EcoRI, respectively. These sequences are utilized to facilitate the mampulation of a specifically amplified DNA sequence encoding a BMP- 12 or BMP- 12 related protein from a species other than human and are thus not derived from the DNA sequence presented in SEQ ID NO: l. Oligonucleotide primer #6 is designed on the basis of nucleotides #607-#626 of SEQ ID NO: 1. Oligonucleotide primer #7 is designed on the basis of the reverse compliment of nucleotides #846-#865 of the
DNA sequence set forth in SEQ ID NO: l.
Oligonucleotide primers #6 and #7 identified above are utilized as primers to allow the amplification of specific BMP- 12 related sequences from genomic DNA derived from species other than humans. The amplification reaction is performed as follows:
Murine genomic DNA (source: strain Balb c) is sheared by repeated passage through a 25 gauge needle, denatured at 100° C for five minutes and then chilled on ice before adding to a reaction mixture containing 200 μM each deoxynucleotide triphosphates (dATP, DGTP, dCTP and dTTP) 10 mM Tris-HCl pH 8.3, 50 mM
KCl, 1.5 mM MgCl2, 0.001 % gelatin, 1.25 units Taq DNA polymerase, 100 pM oligonucleotide primer #6 and 100 pM oligonucleotide primer #7. The reaction mixture is then subjected to thermal cycling in the following manner: 1 minute at
95°C, 1 minute at 55°C, 1 minute at 72°C for forty cycles followed by 10 minutes at 72°C.
The DNA which is specifically amplified by this reaction is ethanol precipitated, digested with the restriction endonucleases BamHI and EcoRI and subjected to agarose gel electrophoresis. A region of the gel, corresponding to the
3

predicted size of the murine BMP-12 or BMP-12 related encoding DNA fragment, is excised and the specifically amplified DNA fragments contained therein are extracted (by electroelution or by other methods known to those skilled in the art) and subcloned in to a plasmid vector, such as pGEM-3 or pBluescript between the BamHI and EcoRI sites of the polylinker. DNA sequence analysis of one of the resulting subclones named mVl, indicates that the specifically amplified DNA sequence contained therein encodes a portion of a protein which appears to be the murine homolog to either the BMP- 12 or VL-1 sequence of the invention. The DNA sequence (SEQ ID NO: 10) and derived amino acid sequence (SEQ ID NO: 11) of this specifically amplified murine DNA fragment are shown in the sequence listings.
Nucleotides #l-#26 of SEQ ID NO: 10 comprise a portion of oligonucleotide #6 and nucleotides #246-#272 comprise a portion of the reverse compliment of oligonucleotide #7 utilized to perform the specific amplification reaction. Nucleotide #27 of SEQ ID NO: 10 appears to be the last nucleotide of a codon triplet, and nucleotides #244-#245 of SEQ ID NO: 10 appear to be the first two nucleotides of a codon triplet. Therefore, nucleotides #28 to #243 of SEQ ID NO: 10 correspond to a partial coding sequence of mVl . Due to the function of oligonucleotides #6 and #7 in initiating the amplification reaction, they may not correspond exactly to the actual sequence encoding the murine homolog to the human BMP- 12 or VL-1 protein of the invention and are therefore not translated in the corresponding amino acid sequence derivation (SEQ ID NO: 11).
Oligonucleotide probes designed on the basis of the specifically amplified murine BMP-12 or VL-1 DNA sequence set forth in SEQ ID NO: 10 can be utilized by those skilled in the art to identify full-length murine BMP- 12 or VL-1 encoding clones (either cDNA or genomic).
DNA sequence analysis of another of the resulting subclones named mV2, indicates that the specifically amplified DNA sequence contained therein encodes a portion of a murine BMP- 12 related sequence of the invention. The DNA sequence (SEQ ID NO: 12) and derived amino acid sequence (SEQ ID NO: 13) of this specifically amplified murine DNA fragment are shown in the sequence listings.
Nucleotides #l-#26 of SEQ ID NO: 12 comprise a portion of oligonucleotide
#6 and nucleotides #246-#272 comprise a portion of the reverse compliment of
S (

oligonucleotide #7 utilized to perform the specific amplification reaction. Nucleotide #27 of SEQ ID NO: 12 appears to be the last nucleotide of a codon triplet, and nucleotides #244-#245 of SEQ ID NO: 12 appear to be the first two nucleotides of a codon triplet. Therefore, nucleotides #28 to #243 of SEQ ID NO: 12 correspond to a partial coding sequence of mV2. Due to the function of oligonucleotides #6 and #7 in initiating the amplification reaction, they may not correspond exactly to the actual sequence encoding the murine BMP- 12 related protein of the invention and are therefore not translated in the corresponding amino acid sequence derivation (SEQ ID NO: 13).
Oligonucleotide probes designed on the basis of the specifically amplified murine BMP-12 related DNA sequence set forth in SEQ ID NO: 12 can be utilized by those skilled in the art to identify full-length murine BMP- 12 related encoding clones (either cDNA or genomic).
DNA sequence analysis of another of the resulting subclones named mV9, indicates that the specifically amplified DNA sequence contained therein encodes a portion of a murine BMP- 12 related sequence of the invention. This sequence appears to be the murine homolog to the human MP52 DNA sequence described at SEQ ID NO:3. The DNA sequence (SEQ ID NO: 14) and derived amino acid sequence (SEQ ID NO: 15) of this specifically amplified murine DNA fragment are shown in the sequence listings.
Nucleotides #l-#26 of SEQ ID NO: 14 comprise a portion of oligonucleotide #6 and nucleotides #246-#272 comprise a portion of the reverse compliment of oligonucleotide #7 utilized to perform the specific amplification reaction. Nucleotide #27 of SEQ ID NO: 14 appears to be the last nucleotide of a codon triplet, and nucleotides #244-#245 of SEQ ID NO: 14 appear to be the first two nucleotides of a codon triplet. Therefore, nucleotides #28 to #243 of SEQ ID NO: 14 correspond to a partial coding sequence of mV9. Due to the function of oligonucleotides #6 and #7 in initiating the amplification reaction, they may not correspond exactly to the actual sequence encoding the murine BMP- 12 related protein of the invention and are therefore not translated in the corresponding amino acid sequence derivation
(SEQ ID NO: 15).
23*

Oligonucleotide probes designed on the basis of the specifically amplified murine BMP-12 related DNA sequence set forth in SEQ ID NO: 14 can be utilized by those skilled in the art to identify full-length murine BMP- 12 related encoding clones (either cDNA or genomic).
Alternatively, oligonucleotide primers #6 and #7 identified above are utilized as primers to allow the specific amplification of a 275 base pair DNA probe, the internal 259 bp of which correspond to nucleotides #607 to #865 of SEQ ID NO: l, from the BMP-12 encoding plasmid subclone PCR1-1#2. This 275bp DNA probe was radioactively labelled with 32P and employed to screen a murine genomic library constructed in the vector λ FIX II (Stratagene catalog #946306). 1 million recombinants of the murine genomic library are plated at a density of approximately 20,000 recombinants per plate on 50 plates. Duplicate nitrocellulose replicas of the recombinant bacteriophage plaques are hybridized, under reduced stringency conditions, to the specifically amplified 333 bp probe in standard hybridization buffer (SHB = 5X SSC, 0.1 % SDS, 5X Denhardt’s, 100 μg/ml salmon sperm DNA) at 60°C overnight. The following day the radioactively labelled oligonucleotide containing hybridization solution is removed an the filters are washed, under reduced stringency conditions, with 2X SSC, 0.1 % SDS at 60°C. Multiple positively hybridizing recombinants are identified and plaque purified. Fragments of the positively hybridizing murine genomic recombinant clones are subcloned into standard plasmid vectors (i.e. pGEM-3) and subjected to DNA sequence analysis.
DNA sequence analysis of one of these subclones named MVR3 indicates that it encodes a portion of the mouse gene corresponding to the PCR product mVl (murine homolog of the human BMP- 12 sequence set forth in SEQ ID NO: l) described above. The partial DNA sequence of this subclone and corresponding amino acid translation are set forth in SEQ ID NO: 29 and SEQ ID NO:30 respectively.
DNA sequence analysis of another one of these subclones named MVR32 indicates that it encodes a portion of the mouse gene corresponding to the PCR product mV2 (murine homolog of the human VL-1 sequence set forth in SEQ ID NO: 7) described above. The partial DNA sequence of this subclone and

corresponding amino acid translation are set forth in SEQ ID NO: 31 and SEQ ID NO:32 respectively.
DNA sequence analysis of another of these subclones named MVR23 indicates that it encodes a portion of the mouse gene corresponding to the PCR product mV9 (murine homolog of the MP-52 sequence set forth in SEQ ID NO: 3) described above.
In a similar manner to that which is described above for identifying and isolating human genomic clones encoding the BMP- 12 protein of the invention, oligonucleotide probe(s) corresponding to the VL-1 encoding sequence set forth in SEQ ID NO: 7 can be designed and utilized to identify human genomic or cDNA sequences encoding the VL-1 (BMP- 13) protein. These oligonucleotides would be designed to regions specific for VL-1 encoding sequences and would therefore be likely to be derived from regions of the lowest degree of nucleotide sequence identity between the specifically amplified VL-1 encoding sequence (SEQ ID NO: 7) and the specifically amplified BMP-12 encoding sequence (SEQ ID NO:5).
Alternatively, oligonucleotide primers #4 and #5 identified above are utilized as primers to allow the specific amplification of a 333 base pair DNA probe, the internal 315 bp of which correspond to nucleotides #571 to #885 of SEQ ID NO: l, from the BMP-12 encoding plasmid subclone PCR1-1#2. This 333 bp DNA probe was radioactively labelled with 32P and employed to screen a human genomic library constructed in the vector λDASH II (Stratagene catalog #945203). 1 million recombinants of the human genomic library are plated at a density of approximately 20,000 recombinants per plate on 50 plates. Duplicate nitrocellulose replicas of the recombinant bacteriophage plaques are hybridized, under reduced stringency conditions, to the specifically amplified 333 bp probe in standard hybridization buffer (SHB = 5X SSC, 0.1 % SDS, 5X Denhardt’s, 100 μg/ml salmon sperm DNA) at 60°C overnight. The following day the radioactively labelled oligonucleotide containing hybridization solution is removed an the filters are washed, under reduced stringency conditions, with 2X SSC, 0.1 % SDS at 60°C. Multiple (approximately 15) positively hybridizing recombinants are identified and plaque purified.
In order to distinguish positively hybridizing recombinants encoding the VL-1 protein of the invention from BMP-12 and other BMP-12-related encoding
3V

recombinants which would be predicted to hybridize positively to the 333 bp DNA probe generated from the BMP-12 encoding plasmid PCR1-1#2 utilized in this screening procedure, the following oligonucleotide probe, based on the VL-1 sequence set forth in SEQ ID NO:7, is designed and synthesized on an automated DNA synthesizer:
#8: TGTATGCGACTTCCCGC [SEQUENCE ID NO: 35] An oligonucleotide corresponding to nucleotides #60 to #76 of SEQ ID NO: 7 which contains 5 nucleotide differences to the corresponding region of the BMP- 12 encoding sequence set forth in SEQ ID NO: l (nucleotides #672 to #689) One of the recombinant bacteriophage clones which hybridizes to the VL-1 oligonucleotide probe #8 is designated λJLDc31. This recombinant bacteriophage clone is plaque purified, a bacteriophage plate stock is made and bacteriophage DNA is isolated from the λJLDc31 human genomic clone. The bacteriophage λJLDc31 has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD «ATCC» under the accession #75922 on October 20, 1994. This deposit meets the requirements of the Budapest Treaty of the International Recognition of the Deposit of Microorganisms for the Puφose of Patent Procedure and Regulations thereunder. The oligonucleotide hybridizing region of this recombinant, λJLDc31, is localized to a 2.5 kb Eco RI fragment. This fragment is subcloned into a plasmid vector (pGEM-3) and DNA sequence analysis is performed. This plasmid subclone is designated pGEMJLDc31/2.5 and has been deposited with the American Type Culture Collection, 12301 Parklawn Drive, Rockville, MD «ATCC» under the accession # 69710 on October 20, 1994. This deposit meets the requirements of the Budapest Treaty of the International Recognition of the Deposit of Microorganisms for the Puφose of Patent Procedure and Regulations thereunder.
The partial DNA sequence (SEQ ID NO: 25) and derived amino acid sequence (SEQ ID NO:26) of a portion of the 2.5 kb DNA insert of the plasmid subclone pGEMJLDc31/2.5 , derived from clone λJLDc31 , are shown in the Sequence Listings
The DNA sequence of a portion of the 2.5 kb EcoRI insert of the plasmid pGEMJLDc31/2.5 is set forth in SEQ ID NO:25.

contains an 912 bp open reading frame, as defined by nucleotides #52 through #963 of SEQ ID NO: 25. As this sequence is derived from a genomic clone it is difficult to determine the boundary between the 5′ extent of coding sequence and the 3′ limit of intervening sequence (intron/non-coding sequence). The entire open reading frame (nucleotides #52 through #963 of SEQ ID NO: 25) encodes a portion of the VL-1 protein of the invention of up to 304 amino acids.
Based on the knowledge of other BMP proteins and other proteins within the TGF-/3 family, it is predicted that the precursor polypeptide would be cleaved at the multibasic sequence Arg-Arg-Arg-Arg in agreement with a proposed consensus proteolytic processing sequence of Arg-X-X-Arg. Cleavage of the VL-1 precursor polypeptide is expected to generate a 120 amino acid mature peptide beginning with the amino acid Thr at position #1 of SEQ ID NO: 26. The processing of VL-1 into the mature form is expected to involve dimerization and removal of the N-terminal region in a manner analogous to the processing of the related protein TGF-/3 [Gentry et al. , Molec & Cell. Biol.. 8:4162 (1988); Derynck et al. Nature. 316:701 (1985)].
It is contemplated therefore that the mature active species of VL-1 comprises a homodimer of two polypeptide subunits, each subunit comprising amino acids #1 to #120 of SEQ ID NO: 26 with a predicted molecular weight of approximately 12,000 daltons. Further active species are contemplated comprising at least amino acids #19 to # 119 or #120 of SEQ ID NO:26, thereby including the first and last conserved cysteine residue.
Using such a method, a clone encoding the mature human VL-1 (BMP-13) was obtained. The nucleotide sequence and corresponding amino acid sequence encoded by this clone are listed in the Sequence Listings at SEQ ID NO: 25 and 26, respectively. EXAMPLE 2 Expression of BMP-12
In order to produce human BMP- 12 proteins, the DNA encoding it is transferred into an appropriate expression vector and introduced into mammalian cells or other preferred eukaryotic or prokaryotic hosts by conventional genetic engineering techniques.
2(e

In order to produce the human BMP- 12 protein in bacterial cells, the following procedure is employed. Expression of BMP- 12 in E. coli
An expression plasmid pALV 1-781, for production of BMP- 12 inE. co/ was constructed which contains the following principal features. Nucleotides 1-2060 contain DNA sequences originating from the plasmid pUC-18 [Norrander et al. , Gene 26: 101-106 (1983)] including sequences containing the gene for /3-lactamase which confers resistance to the antibiotic ampicillin in host E. coli strains, and a colΕl-derived origin of replication. Nucleotides 2061-2221 contain DNA sequences for the major leftward promotor (pL) of bacteriophage λ [Sanger et al. , J. Mol. Biol. 162:729-773 (1982)], including three operator sequences 0L1, 0L2 and 0L3. The operators are the binding sites for λcl repressor protein, intraceUular levels of which control the amount of transcription initiation from pL. Nucleotides 2222-2723 contain a strong ribosome binding sequence included on a sequence derived from nucleotides 35566 to 35472 and 38137 to 38361 from bacteriophage lambda as described in Sanger et al., J. Mol. Biol. 162:729-773 (1982). Nucleotides 2724- 3041 contain a DNA sequence encoding mature BMP- 12 protein with all 3’ untranslated sequence removed. The BMP-12 DNA sequences introduced into the pALV 1-781 expression vector were modified at the 5 ‘end to raise the A+T content without altering the coding capacity. These changes were made to increase the efficiency of translation initiated on the BMP- 12 mRNA in E. coli. Nucleotides 3042-3058 provide a «Linker» DNA sequence containing restriction endonuclease sites. Nucleotides 3059-3127 provide a transcription termination sequence based on that of the E. coli asp A gene [Takagi et al. , Nucl. Acids Res. 13:2063-2074 (1985)]. Nucleotides 3128-3532 are DNA sequences derived from pUC-18.
Plasmid pALV 1-781 was transformed into the E. coli host strain GI724 (F, laclq. lacpL8. ampC: :λcI+) by the procedure of Dagert and Εhrlich, Gene 6:23 (1979). GI724 (ATCC accession No. 55151) contains a copy of the wild-type λcl repressor gene stably integrated into the chromosome at the ampC locus, where it has been placed under the transcriptional control of Salmonella typhimurium trp promotor/operator sequences. In GI724, λCI protein is made only during growth in tryptophan-free media, such as minimal media or a minimal medium supplemented

with casamino acids such as IMC, described above. Addition of tryptophan to a culture of GI724 will repress the trp promoter and turn off synthesis of λcl, gradually causing the induction of transcription from pL promoters if they are present in the cell.
Transformants were selected on 1.5% w/v agar plates containing IMC medium, which is composed of M9 medium [Miller, «Experiments in Molecular Genetics, » Cold Spring Harbor Laboratory, New York (1972)] containing 1 mM MgSO4 and supplemented with 0.5% w/v glucose, 0.2% w/v casamino acids and 100 μg/ml ampicillin. GI724 transformed with pALVl-781 was grown at 37 °C to an A550 of 0.5 in IMC medium containing 100 μg/ml ampicillin. Tryptophan was then added to a final concentration of 100 μg/ml and the culture incubated for a further 4 hours. During this time BMP- 12 protein accumulates within the «inclusion body» fraction. Preparation of Protein Monomer
18 g of frozen cells were weighed out and resuspended in 60ml of 100 mM Tris, 10 mM EDTA, 1 mM phenylmethylsulfonyl fluoride [PMSF], pH 8.3. Cells were lysed by 3 passes through a Microfluidizer™ [model #MCF 100 T]. The inclusion body pellet was obtained by centrifugation at 15,000g at 4°C for 20 minutes. The supernatant was decanted, and the pellet was washed with 100 ml of 100 mM Tris, 1.0 M NaCl, 10 mM EDTA, 1 mM PMSF, pH 8.3. The suspension was centrifuged again at 15,000g at 4°C for 10 minutes, and the supernatant decanted. The pellet was then washed with 100 ml of 100 mM Tris, 10 mM EDTA, 1 % Triton X-100, 1 mM PMSF, pH 8.3. The suspension was centrifuged again at 15,000g at 4°C for 10 minutes, and the supernatant decanted. The pellet was resuspended with 50 ml of 20 mM Tris, 1 mM EDTA, 1 mM PMSF, pH 8.3, containing 1 % DTT in a glass tissue homogenizer. Monomeric BMP- 12 was then solubilized by acidification to pH 2.5 with glacial acetic acid. The soluble fraction was isolated by centrifugation at 15,000g for 20 minutes at 4°C.
The supernatant from this centrifugation was collected and chromatographed over a Sephacryl S-100™ size exclusion column (83 cm x 2.6 cm; «440 ml bed) in 20 ml increments. The Sephacryl S-100™ column was run with a mobile phase of 1 % acetic acid at a flow rate of 1.4 ml/min. Fractions corresponding to BMP-12

monomer were detected by absorbance at 280 nm, and using a computer calculated extinction coefficient of 18200M»-cm~* and molecular weight (11667 daltons). This size exclusion column pooled material was used as starting material for refolding reactions.
As an alternative to the above, 1.0 g of cells stored at -80°C are measured. Solution (3.4 ml 100 mM TRIS, 10 mM EDTA, pH 8.5) is added. The solution is vortexed until cells are well suspended. 40 μl 100 mM PMSF in isopropanol is added. The cells are lysed at 1000 psi in a French pressure cell. The inclusion bodies are centrifuged at 4°C for 20 minutes in an Eppendorf microfuge to form pellets. The supernatants are decanted. To one pellet (out of 4 total) 1.0 ml degassed 8.0 M guanidine hydrochloride, 0.5 M TRIS, 5 mM EDTA, pH 8.5, containing 250 mM DTT is added. The pellet is dissolved and argon is blown over the liquid for 30 seconds. Next the solution is incubated at 37 °C for one hour. Insoluble material is pelleted for 2-3 minutes in an Eppendorf microfuge at 23 °C. 0.5-1.0 ml of supernatant is injected onto a Supelco 2 cm guard cartridge (LC-304), and eluted with an acetonitrile gradient in 0.1 % TFA from 1-70% over 35 minutes. BMP- 12 elutes between 29 and 31 minutes. Fractions are pooled and the protein concentration determined by adsorbance at 280 nanometers versus 0.1 % TFA, using the theoretical extinction coefficient based upon the amino acid content.
As a second alternate method to the above, frozen cell pellets obtained from the E. coli transformants as described above are thawed in 30 ml of TE8.3(100: 10) buffer (100 mM Tris-HCl pH 8.3, 10 mM Na2EDTA, 1 mM PMSF). Cells are lysed by three passes through a Microfluidizer™ [model #MCF 100 T] . The initial inclusion body material pellet is dissolved in 8 M guanidine-HCl, TE8.5(100: 10) buffer (100 mM Tris-HCl pH 8.5, 10 mM Na2EDTA which contained 100 mM DTT, and incubated at 37°C for 1 hour. This material is centrifuged at 12,000 x g for 15 minutes at room temperature. Refolding of BMP-12 protein using CHAPS system
A sufficient volume of the BMP- 12 pool is lyophilized to give 10 μg of protein. 5 μl of glass distilled water is added to redissolve the residue, then 100 μl of refold mix (50 mM Tris, 1.0 M NaCl, 2% 3-(3-chlolamido-
3^

propyl)dimethylammonio-l-propane-sulfate (CHAPS), 5 mM EDTA, 2 mM glutathione (reduced) 1 mM glutathione (oxidized); at pH of approximately 8.5). The solution is gently mixed and stored at 23 °C for 1-4 days. Dimer formation is assessed by running an aliquot on a Novex 16% tricine gel at 125 volts for 2.5 hours, followed by Coomassie Blue staining and destaining.
BMP- 12 dimer was purified using a C4 analytical RP-HPLC (reversed phase- high performance liquid chromatography) column (Vydac 214TP54) which was equilibrated to 1 % B buffer (diluted into A buffer) and was run over 35 minutes, during which the protein elutes, using the following gradient (A buffer = 0.1 % trifluoroacetic acid, B buffer = 95% acetonitrile, 0.1 % trifluoroacetic acid [TFA]), with a flow rate of 1 ml/min:
1-5 minutes 20% B buffer
5-10 minutes 20-30% B buffer
10-30 minutes 30-50% B buffer
30-35 minutes 50-100% B buffer
Protein was monitored by absorbance at 280nm. Peak BMP-12 fractions (eluting between 29 and 31 minutes) were pooled. Purity was assessed by SDS-PAGE. The concentration was determined by absorbance at 280nm, and using the computer calculated extinction coefficient and molecular weight as indicated above. Expression of BMP-12 in mammalian cells:
Another contemplated preferred expression system for biologically active recombinant human BMP-12 is stably transformed mammalian cells.
One skilled in the art can construct mammalian expression vectors by employing the sequence of SEQ ID NO: 1, or other DNA sequences encoding BMP- 12 proteins or other modified sequences and known vectors, such as pCD [Okayama et al., Mol. Cell Biol.. 2: 161-170 (1982)], pJL3, pJL4 [Gough et al. , EMBO , 4:645-653 (1985)] and pMT2 CXM.
The mammalian expression vector pMT2 CXM is a derivative of p91023(b) (Wong et al. , Science 228:810-815, 1985) differing from the latter in that it contains the ampicillin resistance gene in place of the tetracycline resistance gene and further contains a Xhol site for insertion of cDNA clones. The functional elements of pMT2 CXM have been described (Kaufman, R.J., 1985, Proc. Natl. Acad. Sci.

USA 82:689-693) and include the adenovirus VA genes, the SV40 origin of replication including the 72 bp enhancer, the adenovirus major late promoter including a 5′ splice site and the majority of the adenovirus tripartite leader sequence present on adenovirus late mRNAs, a 3′ splice acceptor site, a DHFR insert, the SV40 early polyadenylation site (SV40), and pBR322 sequences needed for propagation in . coli.
Plasmid pMT2 CXM is obtained by EcoRI digestion of pMT2-VWF, which has been deposited with the American Type Culture Collection (ATCC), Rockville, MD (USA) under accession number ATCC 67122. EcoRI digestion excises the cDNA insert present in pMT2-VWF, yielding pMT2 in linear form which can be ligated and used to transform E. coli HB 101 or DH-5 to ampicillin resistance. Plasmid pMT2 DNA can be prepared by conventional methods. pMT2 CXM is then constructed using loopout/in mutagenesis [Morinaga, et al. , Biotechnology 84: 636 (1984). This removes bases 1075 to 1145 relative to the Hind III site near the SV40 origin of replication and enhancer sequences of pMT2. In addition it inserts a sequence containing the recognition site for the restriction endonuclease Xho I. A derivative of pMT2CXM, termed pMT23, contains recognition sites for the restriction endonucleases PstI, Eco RI, Sail and Xhol. Plasmid pMT2 CXM and pMT23 DNA may be prepared by conventional methods. pEMC2/31 derived from pMT21 may also be suitable in practice of the invention. pMT21 is derived from pMT2 which is derived from pMT2-VWF. As described above EcoRI digestion excises the cDNA insert present in pMT-VWF, yielding pMT2 in linear form which can be ligated and used to transform R. Coli HB 101 or DH-5 to ampicillin resistance. Plasmid pMT2 DNA can be prepared by conventional methods. pMT21 is derived from pMT2 through the following two modifications.
First, 76 bp of the 5′ untranslated region of the DHFR cDNA including a stretch of 19 G residues from G/C tailing for cDNA cloning is deleted. In this process, a
Xhol site is inserted to obtain the following sequence immediately upstream from
DHFR. Second, a unique Clal site is introduced by digestion with EcoRV and Xbal, treatment with Klenow fragment of DNA polymerase I, and ligation to a Clal linker
(CATCGATG). This deletes a 250 bp segment from the adenovirus associated RNA i

(VAI) region but does not interfere with VAI RNA gene expression or function. pMT21 is digested with EcoRI and Xhol, and used to derive the vector pEMC2Bl.
A portion of the EMCV leader is obtained from pMT2-ECATl [S.K. Jung, et al, J. Virol 63:1651-1660 (1989)] by digestion with Eco RI and PstI, resulting in a 2752 bp fragment. This fragment is digested with TaqI yielding an Eco RI-TaqI fragment of 508 bp which is purified by electrophoresis on low melting agarose gel. A 68 bp adapter and its complementary strand are synthesized with a 5′ TaqI protruding end and a 3′ Xhol protruding end which has a sequence which matches the EMC virus leader sequence from nucleotide 763 to 827. It also changes the ATG at position 10 within the EMC virus leader to an ATT and is followed by a Xhol site. A three way ligation of the pMT21 Eco Rl-Xhol fragment, the EMC virus EcoRI-TaqI fragment, and the 68 bp oligonucleotide adapter Taql-Xhol adapter resulting in the vector pEMC2/31.
This vector contains the SV40 origin of replication and enhancer, the adenovirus major late promoter, a cDNA copy of the majority of the adenovirus tripartite leader sequence, a small hybrid intervening sequence, an SV40 polyadenylation signal and the adenovirus VA I gene, DHFR and /3-lactamase markers and an EMC sequence, in appropriate relationships to direct the high level expression of the desired cDNA in mammalian cells.
The construction of vectors may involve modification of the BMP- 12 DNA sequences. For instance, BMP- 12 cDNA can be modified by removing the non- coding nucleotides on the 5′ and 3′ ends of the coding region. The deleted non- coding nucleotides may or may not be replaced by other sequences known to be beneficial for expression. These vectors are transformed into appropriate host cells for expression of BMP-12 proteins. Additionally, the sequence of SEQ ID NO:l or other sequences encoding BMP- 12 proteins can be manipulated to express BMP- 12 protein by isolating the mature coding sequence of nucleotides 571 to 882 of SEQ ID NO: l and adding at the 5′ end sequences encoding the complete propeptides of other BMP proteins.
For example, one skilled in the art can make a fusion protein in which the propeptide of BMP-2 is linked in operable fashion to the mature BMP-12 peptide by preparing a DNA vector in which the DNA sequence encoding the BMP-2

propeptide is linked in proper reading frame to the DNA sequence encoding the mature BMP- 12 peptide. The DNA sequence of such a fusion protein is shown in SEQUENCE ID NO:27.
One skilled in the art can manipulate the sequences of SEQ ID NO: l by eliminating or replacing the mammalian regulatory sequences flanking the coding sequence with bacterial sequences to create bacterial vectors for intraceUular or extracellular expression by bacterial cells, as described above. As another example, the coding sequences could be further manipulated (e.g. ligated to other known linkers or modified by deleting non-coding sequences therefrom or altering nucleotides therein by other known techniques). The modified BMP- 12 coding sequence could then be inserted into a known bacterial vector using procedures such as described in T. Taniguchi et al., Proc. Natl Acad. Sci. USA. 77:5230-5233 (1980). This exemplary bacterial vector could then be transformed into bacterial host cells and a BMP- 12 protein expressed thereby. For a strategy for producing extracellular expression of BMP-12 proteins in bacterial cells, see, e.g. European patent application EPA 177,343.
Similar manipulations can be performed for the construction of an insect vector [See, e.g. procedures described in published European patent application 155,476] for expression in insect cells. A yeast vector could also be constructed employing yeast regulatory sequences for intraceUular or extracellular expression of the factors of the present invention by yeast cells. [See, e.g., procedures described in published PCT application WO86/00639 and European patent application EPA 123,289].
A method for producing high levels of a BMP-12 protein of the invention in mammalian cells may involve the construction of cells containing multiple copies of the heterologous BMP- 12 gene. The heterologous gene is linked to an amplifiable marker, e.g. the dihydrofolate reductase (DHFR) gene for which cells containing increased gene copies can be selected for propagation in increasing concentrations of methotrexate (MTX) according to the procedures of Kaufman and Shaφ, J. Mol.
Biol.. 159:601-629 (1982). This approach can be employed with a number of different cell types.
V3

For example, a plasmid containing a DNA sequence for a BMP- 12 of the invention in operative association with other plasmid sequences enabling expression thereof and the DHFR expression plasmid pAdA26SV(A)3 [Kaufman and Shaφ, Mol. Cell. Biol.. 2: 1304 (1982)] can be co-introduced into DHFR-deficient CHO cells, DUKX-BII, by various methods including calcium phosphate coprecipitation and transfection, electroporation or protoplast fusion. DHFR expressing transformants are selected for growth in alpha media with dialyzed fetal calf serum, and subsequently selected for amplification by growth in increasing concentrations of MTX (e.g. sequential steps in 0.02, 0.2, 1.0 and 5uM MTX) as described in Kaufman et al., Mol Cell Biol.. 5:1750 (1983). Transformants are cloned, and biologically active BMP- 12 expression is monitored by the Rosen-modified Sampath- Reddi rat assay described below in Example 5. BMP- 12 expression should increase with increasing levels of MTX resistance. BMP- 12 polypeptides are characterized using standard techniques known in the art such as pulse labeling with [35S] methionine or cysteine and polyacrylamide gel electrophoresis. Similar procedures can be followed to produce other related BMP- 12 proteins. EXAMPLE 3 Preparation of BMP-2 propeptide/BMP-12 mature peptide fusion
In order to construct a vector encoding the BMP-2 propeptide/BMP-12 mature peptide fusion, the following cloning procedure was used to fuse the two sequences together.
First, a DNA restriction enzyme fragment comprising the propeptide of human BMP-2 protein, comprising nucleotides 1 through 843 of SEQ ID NO: 27 is cut from pBMP2ΔEMC. pBMP2ΔEMC is a plasmid derived from lambda U20S-39 (ATCC #40345) comprising the entire coding sequence for human BMP-2 protein with the non-translated 5′ and 3′ sequences of BMP-2 deleted from the vector. The 5′ restriction enzyme used was Bgl II and it cuts pBMP2ΔEMC in the vector at nucleotide 979. The 3′ restriction enzyme used was Mae II and it cuts pBMP2ΔEMC in the BMP-2 propeptide at nucleotide 1925, just short of the carboxy terminus. The resulting 954 base pair product was then gel isolated and gene cleaned. Second, a DNA restriction enzyme fragment comprising the 5′ portion of the human BMP-12 mature peptide DNA sequence, is cut from pPCRl-l#2 Vl-1

(ATCC #69517). The 5′ restriction enzyme used was Eae I and it cuts pPCRl-l#2 VI -1 just 3′ of N-terminus of the human BMP- 12 mature peptide sequence. The resulting 259 base pair product was gel isolated and gene cleaned. Third, two DNA oligos were designed and synthesized, so that when annealed would form a tiny DNA fragment comprising fusion sequence of the extreme 3′ end of the human BMP-2 propeptide and the 5′ end of BMP- 12 mature peptide. The DNA fragment has a 5′ Mae II complimentary sticky end which anneals to the 3′ restriction enzyme fragment comprising the human BMP-2 propeptide. The annealed oligo DNA fragment has a 3′ Eae I complimentary sticky end which anneals to the 5′ of the restriction enzyme fragment comprising the mature peptide of human BMP- 12. The coding strand oligo is named B2/12 and is 13 base pairs long. Next, a DNA fragment encoding the 123 base pairs at the 3′ end of the BMP- 12 mature peptide fragment was obtained as follows. First, a DNA fragment comprising the propeptide of human BMP-2 protein, comprising nucleotides 1 through 846 is PCR amplified from pBMP2ΔEMC. The 5′ primer (oligo 655a) anneals just 5′ of the polylinker. The 3′ primer (BMPpro3) anneals to the BMP-2 propeptide 3′ end and introduces a Bgl II restriction enzyme site by silent sequence mutations. The resulting PCR product was cut with Sal I, which cleaves in the polylinker, and Bgl II. The 850 base pair restriction enzyme fragment (ending in amino acid sequence REKR) was gel isolated and gene cleaned. The BMP- 12 mature peptide was PCR amplified using a 5′ primer (oligo 5-1) encoding the Bgl II restriction enzyme site by silent sequence mutations, and annealing to the 5′ end of a possible mature cleavage product, beginning with amino acid sequence SRCS. The 3′ primer (VI -1 3) anneals to the BMP- 12 mature peptide 3′ end and introduces a Xba I restriction enzyme site after the stop codon. The resulting PCR product was cut with Bgl II and Xba I. The 321 base pair restriction enzyme fragment was gel isolated and gene cleaned. The two restriction fragments were three-way ligated into a previously Sail and Xbal cut vector. The resultant construct was sequenced to check for PCR induced errors and a silent C to T mutation was observed at base pair 185 in the propeptide. This plasmid was designated pREKRSRC. Then pREKRSRC was cut with Bglll and NgoMI, and the vector fragment encompassing the last 123 base pairs of the BMP 12 mature sequence was thereby isolated. The three restriction fragments

and the annealed oligolinker were four-way ligated to yield pREKR-TAL with the
BMP-2 propeptide with the mature cleavage site at the 3′ end fused to the (TAL)
5’ end of the BMP- 12 mature peptide. The coding sequence of the resulting ligated vector is shown in SEQ ID NO: 27.
EXAMPLE 4
Biological Activity of Expressed BMP- 12
To measure the biological activity of the expressed BMP- 12 proteins obtained in Example 2 above, the proteins are recovered from the cell culture and purified by isolating the BMP- 12 proteins from other proteinaceous materials with which they are co-produced as well as from other contaminants. The purified protein may be assayed in accordance with the rat assay described below in Example 5.
Purification is carried out using standard techniques known to those skilled in the art.
Protein analysis is conducted using standard techniques such as SDS-PAGE acrylamide [Laemmli, Nature 227:680 (1970)] stained with Coomassie Blue or silver [Oakley, et al. Anal. Biochem. 105:361 (1980)] and by immunoblot [Towbin, et al. Proc. Natl. Acad. Sci. USA 76:4350 (1979)] Example 5 ROSEN MODIFIED SAMPATH-REDDI ASSAY
A modified version of the rat ectopic implant assay described in Sampath and Reddi, Proc. Natl. Acad. Sci. USA. 80:6591-6595 (1983) is used to evaluate the activity of the BMP- 12 proteins. This modified assay is herein called the Rosen- modified Sampath-Reddi assay. The assay has been widely used to evaluate the bone and cartilage-inducing activity of BMPs. The ethanol precipitation step of the Sampath-Reddi procedure is replaced by dialyzing (if the composition is a solution) or diafiltering (if the composition is a suspension) the fraction to be assayed against water. The solution or suspension is then equilibrated to 0.1 % TFA. The resulting solution is added to 20 mg of rat matrix. A mock rat matrix sample not treated with the protein serves as a control. This material is frozen and lyophilized and the resulting powder enclosed in #5 gelatin capsules. The capsules are implanted subcutaneously in the abdominal thoracic area of 21-49 day old male Long Evans rats. The implants are removed after 10 days. A section of each implant is fixed

and processed for histological analysis. 1 μm gly colmethacry late sections are stained with Von Kossa and acid fuschin to score the amount of induced tendon/ligament-like tissue formation present in each implant.
BMP- 12 was implanted in the rats in doses of 1, 5, 25 and 50 μg per implant for 10 days. BMP-2 at a dose of 5 μg was included as a positive control. For all doses of BMP- 12 tested, no bone or cartilage formation was observed in the implants after ten days. Instead, the implants were filled with tissue resembling embryonic tendon, which is easily recognized by the presence of dense bundles of fibroblasts oriented in the same plane and packed tightly together. [Tendon/ligament-like tissue is described, for example, in Ham and Cormack, Histology (JB Lippincott Co. (1979), pp. 367-369, the disclosure of which is hereby incoφorated by reference]. These findings were reproduced in a second set of assays in which tendon/ligament- like tissues was present in all BMP- 12 containing implants. In contrast, the BMP-2 implants, as expected, showed cartilage and bone formation, but contained no tendon/ligament-like tissue.
The BMP- 12 proteins and related proteins of this invention may be assessed for activity on this assay. Example 6
Using methods in accordance with the above examples, with minor modifications within the skill of the art, human MP52 protein and the murine homologue of BMP- 13 protein were expressed and assayed for tendon/ligament-like tissue inducing activity. All proteins showed comparable results, similar to those described above for human BMP- 12.
The foregoing descriptions detail presently preferred embodiments of the present invention. Numerous modifications and variations in practice thereof are expected to occur to those skilled in the art upon consideration of these descriptions. Those modifications and variations are believed to be encompassed within the claims appended hereto. The disclosure of all references discussed herein are hereby incoφorated by reference.
y v

SEQUENCE LISTING
(1) GENERAL INFORMATION:
(i) APPLICANT: GENETICS INSTITUTE, INC.
PRESIDENT AND FELLOWS OF HARVARD COLLEGE
(ii) TITLE OF INVENTION: TENDON-INDUCING COMPOSITIONS
(iii) NUMBER OF SEQUENCES: 35
(iv) CORRESPONDENCE ADDRESS:
(A) ADDRESSEE: GENETICS INSTITUTE, INC.
(B) STREET: 87 CambridgePark Drive
(C) CITY: Cambridge
(D) STATE: Massachusetts
(E) COUNTRY: USA
(F) ZIP: 02140
(v) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: Patentin Release #1.0, Version #1.25
(vi) CURRENT APPLICATION DATA:
(A) APPLICATION NUMBER:
(B) FILING DATE: Herewith
(C) CLASSIFICATION:
(vii) PRIOR APPLICATION DATA:
(A) APPLICATION NUMBER: US 08/164,103
(B) FILING DATE: 07-DEC-1993
(C) APPLICATION NUMBER: US 08/217,780
(D) FILING DATE: 25-MAR-1994
(E) APPLICATION NUMBER: US 08/333,576
(F) FILING DATE: 02-N0V-1994
(viii) ATTORNEY/AGENT INFORMATION:
(A) NAME: Lazar, Steven R.
(B) REGISTRATION NUMBER: 32,618
(C) REFERENCE/DOCKET NUMBER: 5202D-PCT
(ix) TELECOMMUNICATION INFORMATION:
(A) TELEPHONE: 617 498-8260
(B) TELEFAX: 617 876-5851
(2) INFORMATION FOR SEQ ID NO:l:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 926 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(vii) IMMEDIATE SOURCE:
(B) CLONE: vl-1
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 571..882 (ix) FEATURE:
(A) NAME/KEY: CDS

(B) LOCATION: 1..882
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:l:
GCG CGT AAT ACG ACT CAC TAT AGG GCG AAT TGG GTA CGG GGC CCA GGC 48 Ala Arg Asn Thr Thr His Tyr Arg Ala Asn Trp Val Arg Gly Pro Gly -190 -185 -180 -175
AGC TGG ACT TCT CCG CCG TTG CTG CTG CTG TCC ACG TGC CCG GGC GCC 96 Ser Trp Thr Ser Pro Pro Leu Leu Leu Leu Ser Thr Cys Pro Gly Ala -170 -165 -160
GCC CGA GCG CCA CGC CTG CTG TAC TCG CGG GCA GCT GAG CCC CTA GTC 144 Ala Arg Ala Pro Arg Leu Leu Tyr Ser Arg Ala Ala Glu Pro Leu Val -155 -150 -145
GGT CAG CGC TGG GAG GCG TTC GAC GTG GCG GAC GCC ATG AGG CGC CAC 192 Gly Gin Arg Trp Glu Ala Phe Asp Val Ala Asp Ala Met Arg Arg His -140 -135 -130
CGT CGT GAA CCG CGC CCC CCC CGC GCG TTC TGC CTC TTG CTG CGC GCA 240 Arg Arg Glu Pro Arg Pro Pro Arg Ala Phe Cys Leu Leu Leu Arg Ala -125 -120 -115
GTG GCA GGC CCG GTG CCG AGC CCG TTG GCA CTG CGG CGA CTG GGC TTC 288 Val Ala Gly Pro Val Pro Ser Pro Leu Ala Leu Arg Arg Leu Gly Phe -110 -105 -100 -95
GGC TGG CCG GGC GGA GGG GGC TCT GCG GCA GAG GAG CGC GCG GTG CTA 336 Gly Trp Pro Gly Gly Gly Gly Ser Ala Ala Glu Glu Arg Ala Val Leu -90 -85 -80
GTC GTC TCC TCC CGC ACG CAG AGG AAA GAG AGC TTA TTC CGG GAG ATC 384 Val Val Ser Ser Arg Thr Gin Arg Lys Glu Ser Leu Phe Arg Glu lie -75 -70 -65
CGC GCC CAG GCC CGC GCG CTC GGG GCC GCT CTG GCC TCA GAG CCG CTG 432 Arg Ala Gin Ala Arg Ala Leu Gly Ala Ala Leu Ala Ser Glu Pro Leu -60 -55 -50
CCC GAC CCA GGA ACC GGC ACC GCG TCG CCA AGG GCA GTC ATT GGC GGC 480 Pro Asp Pro Gly Thr Gly Thr Ala Ser Pro Arg Ala Val lie Gly Gly -45 -40 -35
CGC AGA CGG AGG AGG ACG GCG TTG GCC GGG ACG CGG ACA GCG CAG GGC 528 Arg Arg Arg Arg Arg Thr Ala Leu Ala Gly Thr Arg Thr Ala Gin Gly -30 -25 -20 -15
AGC GGC GGG GGC GCG GGC CGG GGC CAC GGG CGC AGG GGC CGG AGC CGC 576 Ser Gly Gly Gly Ala Gly Arg Gly His Gly Arg Arg Gly Arg Ser Arg -10 -5 1
TGC AGC CGC AAG CCG TTG CAC GTG GAC TTC AAG GAG CTC GGC TGG GAC 624 Cys Ser Arg Lys Pro Leu His Val Asp Phe Lys Glu Leu Gly Trp Asp 5 10 15
GAC TGG ATC ATC GCG CCG CTG GAC TAC GAG GCG TAC CAC TGC GAG GGC 672 Asp Trp lie lie Ala Pro Leu Asp Tyr Glu Ala Tyr His Cys Glu Gly 20 25 30
CTT TGC GAC TTC CCT TTG CGT TCG CAC CTC GAG CCC ACC AAC CAT GCC 720 Leu Cys Asp Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala 35 40 45 50
Y

ATC ATT CAG ACG CTG CTC AAC TCC ATG GCA CCA GAC GCG GCG CCG GCC 768 lie lie Gin Thr Leu Leu Asn Ser Met Ala Pro Asp Ala Ala Pro Ala 55 60 65
TCC TGC TGT GTG CCA GCG CGC CTC AGC CCC ATC AGC ATC CTC TAC ATC 816 Ser Cys Cys Val Pro Ala Arg Leu Ser Pro lie Ser lie Leu Tyr lie 70 75 80
GAC GCC GCC AAC AAC GTT GTC TAC AAG CAA TAC GAG GAC ATG GTG GTG 864 Asp Ala Ala Asn Asn Val Val Tyr Lys Gin Tyr Glu Asp Met Val Val 85 90 95
GAG GCC TGC GGC TGC AGG TAGCGCGCGG GCCGGGGAGG GGGCAGCCAC 912
Glu Ala Cys Gly Cys Arg 100
GCGGCCGAGG ATCC 926
(2) INFORMATION FOR SEQ ID NO:2:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 294 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 :
Ala Arg Asn Thr Thr His Tyr Arg Ala Asn Trp Val Arg Gly Pro Gly -190 -185 -180 -175
Ser Trp Thr Ser Pro Pro Leu Leu Leu Leu Ser Thr Cys Pro Gly Ala -170 -165 -160
Ala Arg Ala Pro Arg Leu Leu Tyr Ser Arg Ala Ala Glu Pro Leu Val -155 -150 -145
Gly Gin Arg Trp Glu Ala Phe Asp Val Ala Asp Ala Met Arg Arg His -140 -135 -130
Arg Arg Glu Pro Arg Pro Pro Arg Ala Phe Cys Leu Leu Leu Arg Ala -125 -120 -115
Val Ala Gly Pro Val Pro Ser Pro Leu Ala Leu Arg Arg Leu Gly Phe -110 -105 -100 -95
Gly Trp Pro Gly Gly Gly Gly Ser Ala Ala Glu Glu Arg Ala Val Leu -90 -85 -80
Val Val Ser Ser Arg Thr Gin Arg Lys Glu Ser Leu Phe Arg Glu He -75 -70 -65
Arg Ala Gin Ala Arg Ala Leu Gly Ala Ala Leu Ala Ser Glu Pro Leu -60 -55 -50
Pro Asp Pro Gly Thr Gly Thr Ala Ser Pro Arg Ala Val He Gly Gly -45 -40 -35
Arg Arg Arg Arg Arg Thr Ala Leu Ala Gly Thr Arg Thr Ala Gin Gly -30 -25 -20 -15
Ser Gly Gly Gly Ala Gly Arg Gly His Gly Arg Arg Gly Arg Ser Arg -10 -5 1 rf

Cys Ser Arg Lys Pro Leu His Val Asp Phe Lys Glu Leu Gly Trp Asp 5 10 15
Asp Trp He He Ala Pro Leu Asp Tyr Glu Ala Tyr His Cys Glu Gly 20 25 30
Leu Cys Asp Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala 35 40 45 50
He He Gin Thr Leu Leu Asn Ser Met Ala Pro Asp Ala Ala Pro Ala 55 60 65
Ser Cys Cys Val Pro Ala Arg Leu Ser Pro He Ser He Leu Tyr He 70 75 80
Asp Ala Ala Asn Asn Val Val Tyr Lys Gin Tyr Glu Asp Met Val Val 85 90 95
Glu Ala Cys Gly Cys Arg 100
(2) INFORMATION FOR SEQ ID NO:3 :
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1207 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens
(vii) IMMEDIATE SOURCE:
(B) CLONE: MP52
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 845..1204
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
ACCGGGCGGC CCTGAACCCA AGCCAGGACA CCCTCCCCAA ACAAGGCAGG CTACAGCCCG 60
GACTGTGACC CCAAAAGGAC AGCTTCCCGG AGGCAAGGCA CCCCCAAAAG CAGGATCTGT 120
CCCCAGCTCC TTCCTGCTGA AGAAGGCCAG GGAGCCCGGG CCCCCACGAG AGCCCAAGGA 180
GCCGTTTCGC CCACCCCCCA TCACACCCCA CGAGTACATG CTCTCGCTGT ACAGGACGCT 240
GTCCGATGCT GACAGAAAGG GAGGCAACAG CAGCGTGAAG TTGGAGGCTG GCCTGGCCAA 300
CACCATCACC AGCTTTATTG ACAAAGGGCA AGATGACCGA GGTCCCGTGG TCAGGAAGCA 360
GAGGTACGTG TTTGACATTA GTGCCCTGGA GAAGGATGGG CTGCTGGGGG CCGAGCTCCG 420
GATCTTGCGG AAGAAGCCCT CGGACACGGC CAAGCCAGCG GCCCCCGGAG GCGGGCGGGC 480
TGCCCAGCTG AAGCTGTCCA GCTGCCCCAG CGGCCGGCAG CCGGCCTCCT TGCTGGATGT 540
GCGCTCCGTG CCAGGCCTGG ACGGATCTGG CTGGGAGGTG TTCGACATCT GGAAGCTCTT 600
CCGAAACTTT AAGAACTCGG CCCAGCTGTG CCTGGAGCTG GAGGCCTGGG AACGGGGCAG 660
GGCCGTGGAC CTCCGTGGCC TGGGCTTCGA CCGCGCCGCC CGGCAGGTCC ACGAGAAGGC 720
3-

CTG CGG CTC TTT CGC CAG GCG CCC TCA GCG CCC TGG GGG CCA CCA GCC 142 Leu Arg Leu Phe Arg Gin Ala Pro Ser Ala Pro Trp Gly Pro Pro Ala -170 -165 -160 -155
GGG CCG CTC CAC GTG CAG CTC TTC CCT TGC CTT TCG CCC CTA CTG CTG 190 Gly Pro Leu His Val Gin Leu Phe Pro Cys Leu Ser Pro Leu Leu Leu -150 -145 -140
GAC GCG CGG ACC CTG GAC CCG CAG GGG GCG CCG CCG GCC GGC TGG GAA 238 Asp Ala Arg Thr Leu Asp Pro Gin Gly Ala Pro Pro Ala Gly Trp Glu -135 -130 -125
GTC TTC GAC GTG TGG CAG GGC CTG CGC CAC CAG CCC TGG AAG CAG CTG 286 Val Phe Asp Val Trp Gin Gly Leu Arg His Gin Pro Trp Lys Gin Leu -120 -115 -110
TGC TTG GAG CTG CGG GCC GCA TGG GGC GAG CTG GAC GCC GGG GAG GCC 334 Cys Leu Glu Leu Arg Ala Ala Trp Gly Glu Leu Asp Ala Gly Glu Ala -105 -100 -95
GAG GCG CGC GCG CGG GGA CCC CAG CAA CCG CCG CCC CCG GAC CTG CGG 382 Glu Ala Arg Ala Arg Gly Pro Gin Gin Pro Pro Pro Pro Asp Leu Arg -90 -85 -80 -75
AGT CTG GGC TTC GGC CGG AGG GTG CGG CCT CCC CAG GAG CGG GCC CTG 430 Ser Leu Gly Phe Gly Arg Arg Val Arg Pro Pro Gin Glu Arg Ala Leu -70 -65 -60
CTG GTG GTA TTC ACC AGA TCC CAG CGC AAG AAC CTG TTC GCA GAG ATG 478 Leu Val Val Phe Thr Arg Ser Gin Arg Lys Asn Leu Phe Ala Glu Met -55 -50 -45
CGC GAG CAG CTG GGC TCG GCC GAG GCT GCG GGC CCG GGC GCG GGC GCC 526 Arg Glu Gin Leu Gly Ser Ala Glu Ala Ala Gly Pro Gly Ala Gly Ala -40 -35 -30
GAG GGG TCG TGG CCG CCG CCG TCG GGC GCC CCG GAT GCC AGG CCT TGG 574 Glu Gly Ser Trp Pro Pro Pro Ser Gly Ala Pro Asp Ala Arg Pro Trp -25 -20 -15
CTG CCC TCG CCC GGC CGC CGG CGG CGG CGC ACG GCC TTC GCC AGT CGC 622 Leu Pro Ser Pro Gly Arg Arg Arg Arg Arg Thr Ala Phe Ala Ser Arg -10 -5 1 5
CAT GGC AAG CGG CAC GGC AAG AAG TCC AGG CTA CGC TGC AGC AAG AAG 670 ‘-lis Gly Lys Arg His Gly Lys Lys Ser Arg Leu Arg Cys Ser Lys Lys 10 15 20
‘ CTG CAC GTG AAC TTC AAG GAG CTG GGC TGG GAC GAC TGG ATT ATC 718 Leu His Val Asn Phe Lys Glu Leu Gly Trp Asp Asp Trp He He 25 30 35
Z CTG GAG TAC GAG GCC TAT CAC TGC GAG GGT GTA TGC GAC TTC 766 Leu Glu Tyr Glu Ala Tyr His Cys Glu Gly Val Cys Asp Phe 45 50
«iC TCG CAC CTG GAG CCC ACC AAC CAC GCC ATC ATC CAG ACG 814 7 Ser His Leu Glu Pro Thr Asn His Ala He He .G.ln Thr 60 65 70
*CC ATG GAC CCC GGC TCC ACC CCG CCC AGC. TGC TGC GTG 862 ■r Met Asp Pro Gly Ser Thr Pro Pro Ser Cys Cys Val 75 80 85 CT CCC ATC AGC ATT CTA TAC ATC GAC GCG GGC AAT 910 r Pro He Ser He Leu Tyr He Asp Ala Gly Asn 95 *7

Val Thr Pro Ala Val Met Arg Trp Thr Ala Gin Gly His Ala Asn His -70 -65 -60
Gly Phe Val Val Glu Val Ala His Leu Glu Glu Lys Gin Gly Val Ser -55 -50 -45
Lys Arg His Val Arg He Ser Arg Ser Leu His Gin Asp Glu His Ser -40 -35 -30
Trp Ser Gin He Arg Pro Leu Leu Val Thr Phe Gly His Asp Gly Lys -25 -20 -15
Gly His Pro Leu His Lys Arg Glu Lys Arg Thr Ala Leu Ala Gly Thr -10 -5 1 5
Arg Thr Ala Gin Gly Ser Gly Gly Gly Ala Gly Arg Gly His Gly Arg 10 15 20
Arg Gly Arg Ser Arg Cys Ser Arg Lys Pro Leu His Val Asp Phe Lys 25 30 35
Glu Leu Gly Trp Asp Asp Trp He He Ala Pro Leu Asp Tyr Glu Ala 40 45 50
Tyr His Cys Glu Gly Leu Cys Asp Phe Pro Leu Arg Ser His Leu Glu 55 60 65 70
Pro Thr Asn His Ala He He Gin Thr Leu Leu Asn Ser Met Ala Pro 75 80 85
Asp Ala Ala Pro Ala Ser Cys Cys Val Pro Ala Arg Leu Ser Pro He 90 95 100
Ser He Leu Tyr He Asp Ala Ala Asn Asn Val Val Tyr Lys Gin Tyr 105 110 115
Glu Asp Met Val Val Glu Ala Cys Gly Cys Arg 120 125
(2) INFORMATION FOR SEQ ID NO:29:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1203 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(vii) IMMEDIATE SOURCE:
(B) CLONE: murine MVl
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 2..721
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:29:
A AAG TTC TGC CTG GTG CTG GNG NCG GTG ACG GCC TCG GAG AGC AGN 46
Lys Phe Cys Leu Val Leu XOl X02 Val Thr Ala Ser Glu Ser X03 1 5 10 15
CNG CTG GCC CTG AGA CGA CTG GGC TTC GGC TGN CCG GGC GGT GGC GAC 94 X04 Leu Ala Leu Arg Arg Leu Gly Phe Gly X05 Pro Gly Gly Gly Asp 20 25, 30
(frf

GGC GGC GGC ACT GCG GNC GAG GAG CGC GCG CTG TTG GTG ATC TCC TCC 142 Gly Gly Gly Thr Ala X06 Glu Glu Arg Ala Leu Leu Val He Ser Ser 35 40 45
CGT ACG CAA AGG AAA GAG AGT CTG TTC CGG GAG ATC CGA GCC CAG GCC ‘ 190 Arg Thr Gin Arg Lys Glu Ser Leu Phe Arg Glu He Arg Ala Gin Ala 50 55 60
CGT GCT CTC CGG GCC GCT GCA GAG CCG CCA CCG GAT CCA GGA CCA GGC 238 Arg Ala Leu Arg Ala Ala Ala Glu Pro Pro Pro Asp Pro Gly Pro Gly 65 70 75
GCT GGG TCA CGC AAA GCC AAC CTG GGC GGT CGC AGG CGG CAG CGG ACT 286 Ala Gly Ser Arg Lys Ala Asn Leu Gly Gly Arg Arg Arg Gin Arg Thr 80 85 90 95
GCG CTG GCT GGG ACT CGG GGA GNG NAG GGA AGC GGT GGT GGC GGC GGT 334 Ala Leu Ala Gly Thr Arg Gly X07 X08 Gly Ser Gly Gly Gly Gly Gly 100 105 110
GGC GGT GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GGC GCA 382 Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala 115 120 125
GGC AGG GGC CAC GGG CGC AGA GGC CGG AGC CGC TGC GGT CGC AAG TCA 430 Gly Arg Gly His Gly Arg Arg Gly Arg Ser Arg Cys Gly Arg Lys Ser 130 135 140
CTG CAC GTG GAC TTT AAG GAG CTG GGC TGG GAC GAC TGG ATC ATC GCG 478 Leu His Val Asp Phe Lys Glu Leu Gly Trp Asp Asp Trp He He Ala 145 150 155
CCA TTA GAC TAC GAG GCA TAC CAC TGC GAG GGC GTT TGC GAC TTT CCT 526 Pro Leu Asp Tyr Glu Ala Tyr His Cys Glu Gly Val Cys Asp Phe Pro 160 165 170 175
CTG CGC TCG CAC CTG GAG CCT ACC AAC CAC GCC ATC ATT CAG ACG CTG 574 Leu Arg Ser His Leu Glu Pro Thr Asn His Ala He He Gin Thr Leu 180 185 190
CTC AAC TCC ATG GCG CCC GAC GCT GCG CCA GCC TCC TGC TGC GTG CCC 622 Leu Asn Ser Met Ala Pro Asp Ala Ala Pro Ala Ser Cys Cys Val Pro 195 200 205
GCA AGG CTC AGT CCC ATC AGC ATT CTC TAC ATC GAT GCC GCC AAC AAC 670 Ala Arg Leu Ser Pro He Ser He Leu Tyr He Asp Ala Ala Asn Asn 210 215 220
GTG GTC TAC AAG CAG TAC GAA GAC ATG GTG GTG GAG GCC TGC GGC TGC 718 Val Val Tyr Lys Gin Tyr Glu Asp Met Val Val Glu Ala Cys Gly Cys 225 230 235
AGG TAGCATGCGG TCTGGGGAGG GTCTGGCCGC CCAGGACCCT AGCTCAAGAG 771
Arg
240
CAGGTGTCAT CAGGCCCGAG GGACGGCGGA CTATGGCCTC TGCCAGCACA GAGGAGAGCA 831
CACAGTTAAC ACTCACATTT ACACACTCCT TCACTCACGC ACATGTTTAC CGTGGACGGC 891
AGGCGCTAAA AGCCTTGCTT ATTTGCTACC ATTGATACAA ACCTCTGTCC TTTTCGGGAG 951
AGGGAAGGGC ATCTGTGTTT ATGTTGCAGT AATTGGCACT AAATCCAAGT AGAAATGGGT 1011
TAGCATTGGA TTCTCCTTTT AGTTGGAGGC GGTGTGGCTG GATTCCTGAC GTTGGATATG 1071
GAGTGCACTG CAGGGCTGGG ATACCCAGAT TCTCTGGAGT GGGCATTGGG AACCTTCAAA 1131 is> 9

AGTAAGGAGC CACTGGGGCT TGGGAGGGAG CACCCGGTTC CTAAACAAGT CTGATGTGTA 1191 CTGCTCAGTT TG 1203
(2) INFORMATION FOR SEQ ID NO:30:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 240 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:30:
Lys Phe Cys Leu Val Leu XOl X02 Val Thr Ala Ser Glu Ser X03 X04 1 5 10 15
Leu Ala Leu Arg Arg Leu Gly Phe Gly X05 Pro Gly Gly Gly Asp Gly 20 25 30
Gly Gly Thr Ala X06 Glu Glu Arg Ala Leu Leu Val He Ser Ser Arg 35 40 45
Thr Gin Arg Lys Glu Ser Leu Phe Arg Glu He Arg Ala Gin Ala Arg 50 55 60
Ala Leu Arg Ala Ala Ala Glu Pro Pro Pro Asp Pro Gly Pro Gly Ala 65 70 75 80
Gly Ser Arg Lys Ala Asn Leu Gly Gly Arg Arg Arg Gin Arg Thr Ala 85 90 95
Leu Ala Gly Thr Arg Gly X07 X08 Gly Ser Gly Gly Gly Gly Gly Gly 100 105 110
Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Gly Ala Gly 115 120 125
Arg Gly His Gly Arg Arg Gly Arg Ser Arg Cys Gly Arg Lys Ser Leu 130 135 140
His Val Asp Phe Lys Glu Leu Gly Trp Asp Asp Trp He He Ala Pro 145 150 155 160
Leu Asp Tyr Glu Ala Tyr His Cys Glu Gly Val Cys Asp Phe Pro Leu 165 170 175
Arg Ser His Leu Glu Pro Thr Asn His Ala He He Gin Thr Leu Leu 180 185 190
Asn Ser Met Ala Pro Asp Ala Ala Pro Ala Ser Cys Cys Val Pro Ala 195 200 205
Arg Leu Ser Pro He Ser He Leu Tyr He Asp Ala Ala Asn Asn Val 210 215 220
Val Tyr Lys Gin Tyr Glu Asp Met Val Val Glu Ala Cys Gly Cys Arg 225 230 235 240
(2) INFORMATION FOR SEQ ID NO:31:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1046 base pairs
(B) TYPE: nucleic acid o

(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: MURINE MV2
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 2..790
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:31:
A AGA AAA CAA GCT TGC ATT CCT GCA GGT CCG ACT CTA AGA GGA TCC 46
Arg Lys Gin Ala Cys He Pro Ala Gly Pro Thr Leu Arg Gly Ser 1 5 10 15
TCA GGG ACC CAA CCC AGG CCG GCT GGG AAG TCT TTC GAC GTG TGG CAG 94 Ser Gly Thr Gin Pro Arg Pro Ala Gly Lys Ser Phe Asp Val Trp Gin 20 25 30
GGC CTG CGC CCT CAG CCT TGG AAG CAG CTG TGC CTG GAG TTG CGG GCA 142 Gly Leu Arg Pro Gin Pro Trp Lys Gin Leu Cys Leu Glu Leu Arg Ala 35 40 45
GCC TGG GGT GAG CTG GAC RCC GGG GAT ACG GGG GCG CGC GCG AGG GGT 190 Ala Trp Gly Glu Leu Asp XOl Gly Asp Thr Gly Ala Arg Ala Arg Gly 50 55 60
CCC CAG CAG CCA CCG CCT CTG GAC CTG CGG AGT CTG GGC TTC GGT CGG 238 Pro Gin Gin Pro Pro Pro Leu Asp Leu Arg Ser Leu Gly Phe Gly Arg 65 70 75
AGG GTG AGA CCG CCC CAG GAG CGC GCC CTG CTT GTA GTG TTC ACC AGA 286 Arg Val Arg Pro Pro Gin Glu Arg Ala Leu Leu Val Val Phe Thr Arg 80 85 90 95
TCG CAG CGC AAG AAC CTG TTC ACT GAG ATG CAT GAG CAG CTG GGC TCT 334 Ser Gin Arg Lys Asn Leu Phe Thr Glu Met His Glu Gin Leu Gly Ser 100 105 110
GCA GAG GCT GCG GGA GCC GAG GGG TCA TGT CCA GCG CCG TCG GGC TCC 382 Ala Glu Ala Ala Gly Ala Glu Gly Ser Cys Pro Ala Pro Ser Gly Ser 115 120 125
CCA GAC ACC GGG TCT TGG CTG CCC TCG CCC GGC CGC CGG CGG CGA CGC 430 Pro Asp Thr Gly Ser Trp Leu Pro Ser Pro Gly Arg Arg Arg Arg Arg 130 135 140
ACC GCC TTC GCC AGC CGT CAC GGC AAG CGA CAT GGC AAG AAG TCC AGG 478 Thr Ala Phe Ala Ser Arg His Gly Lys Arg His Gly Lys Lys Ser Arg 145 150 155
CTG CGC TGC AGC AGA AAG CCT CTG CAC GTG AAT TTT AAG GAG TTA GGC 526 Leu Arg Cys Ser Arg Lys Pro Leu His Val Asn Phe Lys Glu Leu Gly 160 165 170 175
TGG GAC GAC TGG ATT ATC GCG CCC CTA GAG TAC GAG GCC TAT CAC TGC 574 Trp Asp Asp Trp He He Ala Pro Leu Glu Tyr Glu Ala Tyr His Cys 180 185 190
7(

GAG GGC GTG TGC GAC TTT CCG CTG CGC TCG CAC CTT GAG CCC ACT AAC 622 Glu Gly Val Cys Asp Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn 195 200 205
CAT GCC ATC ATT CAG ACG CTG ATG AAC TCC ATG GAC CCG GGC TCC ACC 670 His Ala He He Gin Thr Leu Met Asn Ser Met Asp Pro Gly Ser Thr 210 215 220
CCG CCT AGC TGC TGC GTT CCC ACC AAA CTG ACT CCC ATT AGC ATC CTG 718 Pro Pro Ser Cys Cys Val Pro Thr Lys Leu Thr Pro He Ser He Leu 225 230 235
TAC ATC GAC GCG GGC AAT AAT GTN GTC TAC AAG CAG TAT GAG GAC ATG 766 Tyr He Asp Ala Gly Asn Asn X02 Val Tyr Lys Gin Tyr Glu Asp Met 240 245 250 255
GTG GTG GAG TCC TGC GGC TGT AGG TAGCGGTGCT GTCCCGCCAC CTGGGCCAGG 820 Val Val Glu Ser Cys Gly Cys Arg 260
GACCATGGAG GGAGGCCTGA CTGCCGAGAA AGGAGCAGGA GCTGGCCTTG GAAGAGGCCA 880
CAGGTGGGGG ACAGCCTGAA AGTAGGAGCA CAGTAAGAAG CAGCCCAGCC TTCCCAGAAC 940
CTTCCAATCC CCCAACCCAG AAGCAGCTAA GGGGTTTCAC AACTTTTGGC CTTGCCAGCC 1000
TGGAAAGACT AGACAAGAGG GATTCTTCTC TTTTTATTAT GGCTTG 1046
(2) INFORMATION FOR SEQ ID NO:32:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 263 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:32:
Arg Lys Gin Ala Cys He Pro Ala Gly Pro Thr Leu Arg Gly Ser Ser 1 5 10 15
Gly Thr Gin Pro Arg Pro Ala Gly Lys Ser Phe Asp Val Trp Gin Gly 20 25 30
Leu Arg Pro Gin Pro Trp Lys Gin Leu Cys Leu Glu Leu Arg Ala Ala 35 40 45
Trp Gly Glu Leu Asp XOl Gly Asp Thr Gly Ala Arg Ala Arg Gly Pro 50 55 60
Gin Gin Pro Pro Pro Leu Asp Leu Arg Ser Leu Gly Phe Gly Arg Arg 65 70 75 80
Val Arg Pro Pro Gin Glu Arg Ala Leu Leu Val Val Phe Thr Arg Ser 85 90 95
Gin Arg Lys Asn Leu Phe Thr Glu Met His Glu Gin Leu Gly Ser Ala 100 105 110
Glu Ala Ala Gly Ala Glu Gly Ser Cys Pro Ala Pro Ser Gly Ser Pro 115 120 125
Asp Thr Gly Ser Trp Leu Pro Ser Pro Gly Arg Arg Arg Arg Arg Thr 130 135 140
7^

Ala Phe Ala Ser Arg His Gly Lys Arg His Gly Lys Lys Ser Arg Leu 145 150 155 160
Arg Cys Ser Arg Lys Pro Leu His Val Asn Phe Lys Glu Leu Gly Trp 165 170 175
Asp Asp Trp He He Ala Pro Leu Glu Tyr Glu Ala Tyr His Cys Glu 180 185 190
Gly Val Cys Asp Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His 195 200 205
Ala He He Gin Thr Leu Met Asn Ser Met Asp Pro Gly Ser Thr Pro 210 215 220
Pro Ser Cys Cys Val Pro Thr Lys Leu Thr Pro He Ser He Leu Tyr 225 230 235 240
He Asp Ala Gly Asn Asn X02 Val Tyr Lys Gin Tyr Glu Asp Met Val 245 250 255
Val Glu Ser Cys Gly Cys Arg 260
(2) INFORMATION FOR SEQ ID NO:33:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 1345 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic) (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO
(vii) IMMEDIATE SOURCE:
(B) CLONE: HUMAN VI-1
(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION: 138..1301
(ix) FEATURE:
(A) NAME/KEY: mat_peptide
(B) LOCATION: 990..1301
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:33:
AACTATAGCA CCTGCAGTCC CTGGTCTTGG GTGTAGGGGT GCGCTCCTGG TCCCGCGGCT 60
CAGGGATATG CAGTGACCAA TGGGTTGTTG GCCTGATGGG ACTTTTGGCT TGCTAAACCA 120
AAGCTCGGTT CGGATAG CCC GGG CGA AGA CGT CCG CTG CTC TGG GCC AGG 170
Pro Gly Arg Arg Arg Pro Leu Leu Trp Ala Arg -284 -280 -275
CTG GCA GCG TTC AGG CTG GGG CAG AGA CGC GGA GTC GGG CGC TGG CTC 218 Leu Ala Ala Phe Arg Leu Gly Gin Arg Arg Gly Val Gly Arg Trp Leu -27Q -265 -260

CAA CAG GCC TGG CTC CCA CAT CGA AGA CAG CTG GGC CAT TTG CTG TTA 266 Gin Gin Ala Trp Leu Pro His Arg Arg Gin Leu Gly His Leu Leu Leu -255 -250 -245
GGA GGC CCC GCG CTG ACA GTG TGC AGG ATT TGC TCT TAC ACA GCT CTT 314 Gly Gly Pro Ala Leu Thr Val Cys Arg He Cys Ser Tyr Thr Ala Leu -240 -235 -230
TCT CTC TGT CCC TGC CGG TCC CCC GCA GAC GAA TCG GCA GCC GAA ACA 362 Ser Leu Cys Pro Cys Arg Ser Pro Ala Asp Glu Ser Ala Ala Glu Thr -225 -220 -215 -210
GGC CAG AGC TTC CTG TTC GAC GTG TCC AGC CTT AAC GAC GCA GAC GAG 410 Gly Gin Ser Phe Leu Phe Asp Val Ser Ser Leu Asn Asp Ala Asp Glu -205 -200 -195
GTG GTG GGT GCC GAG CTG CGC GTG CTG CGC CGG GGA TCT CCA GAG TCG 458 Val Val Gly Ala Glu Leu Arg Val Leu Arg Arg Gly Ser Pro Glu Ser -190 -185 -180
GGC CCA GGC AGC TGG ACT TCT CCG CCG TTG CTG CTG CTG TCC ACG TGC 506 Gly Pro Gly Ser Trp Thr Ser Pro Pro Leu Leu Leu Leu Ser Thr Cys -175 -170 -165
CCG GGC GCC GCC CGA GCG CCA CGC CTG CTG TAC TCG CGG GCA GCT GAG 554 Pro Gly Ala Ala Arg Ala Pro Arg Leu Leu Tyr Ser Arg Ala Ala Glu -160 -155 -150
CCC CTA GTC GGT CAG CGC TGG GAG GCG TTC GAC GTG GCG GAC GCC ATG 602 Pro Leu Val Gly Gin Arg Trp Glu Ala Phe Asp Val Ala Asp Ala Met -145 -140 -135 -130
AGG CGC CAC CGT CGT GAA CCG CGC CCC CCC CGC GCG TTC TGC CTC TTG 650 Arg Arg His Arg Arg Glu Pro Arg Pro Pro Arg Ala Phe Cys Leu Leu -125 -120 -115
CTG CGC GCA GTG GCA GGC CCG GTG CCG AGC CCG TTG GCA CTG CGG CGA 698 Leu Arg Ala Val Ala Gly Pro Val Pro Ser Pro Leu Ala Leu Arg Arg -110 -105 -100
CTG GGC TTC GGC TGG CCG GGC GGA GGG GGC TCT GCG GCA GAG GAG CGC 746 Leu Gly Phe Gly Trp Pro Gly Gly Gly Gly Ser Ala Ala Glu Glu Arg -95 -90 -85
GCG GTG CTA GTC GTC TCC TCC CGC ACG CAG AGG AAA GAG AGC TTA TTC 794 Ala Val Leu Val Val Ser Ser Arg Thr Gin Arg Lys Glu Ser Leu Phe -80 -75 -70
CGG GAG ATC CGC GCC CAG GCC CGC GCG CTC GGG GCC GCT CTG GCC TCA 842 Arg Glu He Arg Ala Gin Ala Arg Ala Leu Gly Ala Ala Leu Ala Ser -65 -60 -55 -50
GAG CCG CTG CCC GAC CCA GGA ACC GGC ACC GCG TCG CCA AGG GCA GTC 890 Glu Pro Leu Pro Asp Pro Gly Thr Gly Thr Ala Ser Pro Arg Ala Val -45 -40 -35
ATT GGC GGC CGC AGA CGG AGG AGG ACG GCG TTG GCC GGG ACG CGG ACA 938 He Gly Gly Arg Arg Arg Arg Arg Thr Ala Leu Ala Gly Thr Arg Thr -30 -25 -20
GCG CAG GGC AGC GGC GGG GGC GCG GGC CGG GGC CAC GGG CGC AGG GGC 986 Ala Gin Gly Ser Gly Gly Gly Ala Gly Arg Gly His Gly Arg Arg Gly -15 -10 -5
CGG AGC CGC TGC AGC CGC AAG CCG TTG CAC GTG GAC TTC AAG GAG CTC 1034 Arg Ser Arg Cys Ser Arg Lys Pro Leu His Val Asp Phe Lys Glu Leu 1 5 η ff 10 15

GGC TGG GAC GAC TGG ATC ATC GCG CCG CTG GAC TAC GAG GCG TAC CAC 1082 Gly Trp Asp Asp Trp He He Ala Pro Leu Asp Tyr Glu Ala Tyr His 20 25 30
TGC GAG GGC CTT TGC GAC TTC CCT TTG CGT TCG CAC CTC GAG CCC ACC -1130 Cys Glu Gly Leu Cys Asp Phe Pro Leu Arg Ser His Leu Glu Pro Thr 35 40 . 45
AAC CAT GCC ATC ATT CAG ACG CTG CTC AAC TCC ATG GCA CCA GAC GCG 1178 Asn His Ala He He Gin Thr Leu Leu Asn Ser Met Ala Pro Asp Ala 50 55 60
GCG CCG GCC TCC TGC TGT GTG CCA GCG CGC CTC AGC CCC ATC AGC ATC 1226 Ala Pro Ala Ser Cys Cys Val Pro Ala Arg Leu Ser Pro He Ser He 65 70 75
CTC TAC ATC GAC GCC GCC AAC AAC GTT GTC TAC AAG CAA TAC GAG GAC 1274 Leu Tyr He Asp Ala Ala Asn Asn Val Val Tyr Lys Gin Tyr Glu Asp 80 85 90 95
ATG GTG GTG GAG GCC TGC GGC TGC AGG TAGCGCGCGG GCCGGGGAGG 1321
Met Val Val Glu Ala Cys Gly Cys Arg 100
GGGCAGCCAC GCGGCCGAGG ATCC 1345
(2) INFORMATION FOR SEQ ID NO:34:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 388 amino acids
(B) TYPE: amino acid (D) TOPOLOGY: linear
(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:34:
Pro Gly Arg Arg Arg Pro Leu Leu Trp Ala Arg Leu Ala Ala Phe Arg -284 -280 -275 -270
Leu Gly Gin Arg Arg Gly Val Gly Arg Trp Leu Gin Gin Ala Trp Leu -265 -260 -255
Pro His Arg Arg Gin Leu Gly His Leu Leu Leu Gly Gly Pro Ala Leu -250 -245 -240
Thr Val Cys Arg He Cys Ser Tyr Thr Ala Leu Ser Leu Cys Pro Cys -235 -230 -225
Arg Ser Pro Ala Asp Glu Ser Ala Ala Glu Thr Gly Gin Ser Phe Leu -220 -215 -210 -205
Phe Asp Val Ser Ser Leu Asn Asp Ala Asp Glu Val Val Gly Ala Glu -200 -195 -190
Leu Arg Val Leu Arg Arg Gly Ser Pro Glu Ser Gly Pro Gly Ser Trp -185 -180 -175
Thr Ser Pro Pro Leu Leu Leu Leu Ser Thr Cys Pro Gly Ala Ala Arg -170 -165 -160
Ala Pro Arg Leu Leu Tyr Ser Arg Ala Ala Glu Pro Leu Val Gly Gin -155 -150 -145
Arg Trp Glu Ala Phe Asp Val Ala Asp Ala Met Arg Arg His Arg Arg -140 -135 _ -130 -125
*?*3

Glu Pro Arg Pro Pro Arg Ala Phe Cys Leu Leu Leu Arg Ala Val Ala -120 -115 -110
Gly Pro Val Pro Ser Pro Leu Ala Leu Arg Arg Leu Gly Phe Gly Trp -105 -100 -95
Pro Gly Gly Gly Gly Ser Ala Ala Glu Glu Arg Ala Val Leu Val Val -90 -85 -80
Ser Ser Arg Thr Gin Arg Lys Glu Ser Leu Phe Arg Glu He Arg Ala -75 -70 -65
Gin Ala Arg Ala Leu Gly Ala Ala Leu Ala Ser Glu Pro Leu Pro Asp -60 -55 -50 -45
Pro Gly Thr Gly Thr Ala Ser Pro Arg Ala Val He Gly Gly Arg Arg -40 -35 -30
Arg Arg Arg Thr Ala Leu Ala Gly Thr Arg Thr Ala Gin Gly Ser Gly -25 -20 -15
Gly Gly Ala Gly Arg Gly His Gly Arg Arg Gly Arg Ser Arg Cys Ser -10 -5 1
Arg Lys Pro Leu His Val Asp Phe Lys Glu Leu Gly Trp Asp Asp Trp 5 10 15 20
He He Ala Pro Leu Asp Tyr Glu Ala Tyr His Cys Glu Gly Leu Cys 25 30 35
Asp Phe Pro Leu Arg Ser His Leu Glu Pro Thr Asn His Ala He He 40 45 50
Gin Thr Leu Leu Asn Ser Met Ala Pro Asp Ala Ala Pro Ala Ser Cys 55 60 65
Cys Val Pro Ala Arg Leu Ser Pro He Ser He Leu Tyr He Asp Ala 70 75 80
Ala Asn Asn Val Val Tyr Lys Gin Tyr Glu Asp Met Val Val Glu Ala 85 90 95 100
Cys Gly Cys Arg
(2) INFORMATION FOR SEQ ID NO:35:
(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 17 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear
(ii) MOLECULE TYPE: DNA (genomic)
(iii) HYPOTHETICAL: NO
(iv) ANTI-SENSE: NO ‘
(vi) ORIGINAL SOURCE:
(C) INDIVIDUAL ISOLATE: primer number 8
(xi) SEQUENCE DESCRIPTION: SEQ ID NO:35: TGTATGCGAC TTCCCGC 17

Claims (28)

What is claimed is:

1. A DNA molecule comprising an isolated DNA sequence encoding a BMP- 12 related protein.

2. A DNA molecule according to claim 1, wherein said DNA sequence is selected from the group consisting of:
(a) nucleotides #496, #571 or #577 to #882 of SEQ ID NO: l;
(b) nucleotides #605 or #659 to #964 of SEQ ID NO:25; and
(c) sequences which hybridize to (a) or (b) under stringent hybridization conditions and encode a BMP- 12 related protein which exhibits the ability to form tendon/ligament-like tissue.

3. A DNA molecule comprising the DNA sequence of claim 1 wherein said DNA sequence is selected from the group consisting of:
(a) nucleotides encoding for amino acids #-25, #1 or #3 to #104 of SEQ ID NO:2;
(b) in a 5′ to 3′ direction, nucleotides encoding a propeptide selected from the group consisting of native BMP- 12 propeptide and a BMP protein propeptide; and nucleotides encoding for amino acids #-25, #1 or #3 to #104 of SEQ ID NO:2; and (c) nucleotides encoding for amino acids #1 or #19 to #120 of SEQ ID
NO:26;
(d) in a 5′ to 3’ direction, nucleotides encoding a propeptide selected from the group consisting of native BMP- 12 propeptide and a BMP protein propeptide; and nucleotides encoding for amino acids #1 or #19 to #120 of SEQ ID NO:26;
(e) sequences which hybridize to any of (a) through (d) under stringent hybridization conditions and encode a BMP-12 related protein which exhibits the ability to form cartilage and/or bone.

4. A host cell transformed with a DNA molecule according to claim 1.

5. A host cell transformed with the DNA molecule of claim 2.

6. A host cell transformed with the DNA molecule of claim 3.
ni

7. An isolated DNA molecule having a sequence encoding a BMP- 12 protein which is characterized by the ability to induce the formation of tendon/ligament-like tissue, said DNA molecule comprising a DNA sequence selected from the group consisting of: (a) nucleotide #496, #571 or #577 to #882 of SEQ ID NO: 1;
(b) nucleotide #605 or #659 to #964 of SEQ ID NO:25; and
(c) naturally occurring allelic sequences and equivalent degenerative codon sequences of (a) or (b).

8. A host cell transformed with the DNA molecule of claim 7.

9. A vector comprising a DNA molecule of claim 7 in operative association with an expression control sequence therefor.

10. A host cell transformed with the vector of claim 9.

11. A method for producing a purified BMP-12 protein, said method comprising the steps of: (a) culturing a host cell transformed with a DNA molecule according to claim 2, comprising a nucleotide sequence encoding a BMP- 12 related protein; and
(b) recovering and purifying said BMP- 12 related protein from the culture medium.

12. A method for producing a purified BMP-12 related protein said method comprising the steps of:
(a) culturing a host cell transformed with a DNA molecule according to claim 3, comprising a nucleotide sequence encoding a BMP-12 related protein; and (b) recovering and purifying said BMP- 12 related protein from the culture medium.

13. A method for producing a purified BMP- 12 related protein said method comprising the steps of:
(a) culturing a host cell transformed with a DNA molecule according to claim 7, comprising a nucleotide sequence encoding a BMP-12 related protein; and (b) recovering and purifying said BMP- 12 related protein from the culture medium.

14. A purified polypeptide comprising an amino acid sequence selected from the following group: (a) from amino acid #-25 to amino acid #104 as set forth in SEQ ID
NO:2;
(b) from amino acid #1 to amino acid #104 as set forth in SEQ ID NO:2.
(c) from amino acid #3 to amino acid #104 as set forth in SEQ ID NO:2.
(d) from amino acid #1 to amino acid #120 as set forth in SEQ ID NO:26; and
(d) from amino acid #19 to amino acid #120 as set forth in SEQ ID NO:26.

15. A purified polypeptide wherein said polypeptide is in the form of a dimer comprised of two subumts, each with the amino acid sequence of claim 14.

16. A purified protein produced by the steps of
(a) culturing a cell transformed with a DNA molecule comprising the nucleotide sequence from nucleotide #496, #571 or #577 to #882 as shown in SEQ ID NO: 1; and (b) recovering and purifying from said culture medium a protein comprising the amino acid sequence from amino acid #-25, amino acid #1 or amino acid #3 to amino acid #104 as shown in SEQ ID NO:2.

17. A purified BMP- 12 related protein characterized by the ability to induce the formation of tendon/ligament-like tissue.

18. A pharmaceutical composition comprising an effective amount of the
BMP-12 related protein of claim 17 in admixture with a pharmaceutically acceptable vehicle.

19. A method for inducing tendon/ligament-like tissue formation in a patient in need of same comprising administering to said patient an effective amount of the composition of claim 18.
15

20. A pharmaceutical composition for tendon/ligament-like tissue healing and tissue repair said composition comprising an effective amount of the protein of a BMP- 12 related protein in a pharmaceutically acceptable vehicle.

21. A method for treating tendinitis, or other tendon or ligament defect in a patient in need of same, said method comprising administering to said patient an effective amount of the composition of claim 20.

22. A chimeric DNA molecule comprising a DNA sequence encoding a propeptide from a member of the TGF-/3 superfamily of proteins linked in correct reading frame to a DNA sequence encoding a BMP- 12 related polypeptide.

23. A chimeric DNA molecule according to claim 22, wherein the propeptide is the propeptide from BMP-2.

24. A heterodimeric protein molecule comprising one monomer having the amino acid sequence of the polypeptide of claim 14, and one monomer having the amino acid sequence of a protein of the TGF- 3 superfamily.

25. A method for inducing tendon/ligament-like tissue formation in a patient in need of same comprising administering to said patient an effective amount of a composition comprising a protein encoded by a DNA sequence selected from the group consisting of: (a) nucleotides #496, #571 or #577 to #882 of SEQ ID NO: l;
(b) nucleotides #845 or #899 to #1204 of SEQ ID NO:3;
(c) nucleotides #605 or #659 to #964 of SEQ ID NO:25; and
(d) sequences which hybridize to (a), (b) or (c) under stringent hybridization conditions and encode a protein which exhibits the ability to form tendon/ligament-like tissue.

26. A method for inducing tendon/ligament-like tissue formation in a patient in need of same comprising admimstering to said patient an effective amount of the composition comprising a tendon/ligament-like tissue inducing protein having an amino acid sequence selected from the group consisting of: (a) amino acids #-25, #1 or #3 to #104 of SEQ ID NO:2;
(b) amino acids #1 or #19 to #120 of SEQ ID NO:4;
(c) amino acids #1 or #19 to #120 of SEQ ID NO:26; and
«0 (d) mutants and/or variants of (a), (b) or (c) which exhibit the ability to form tendon and/or ligament.

27. A pharmaceutical composition for tendon/ligament-like tissue repair, said composition comprising an effective amount of a BMP- 12 related protein in a pharmaceutically acceptable vehicle.

28. A method for treating tendinitis, or other tendon or ligament defect in a patient in need of same, said method comprising administering to said patient an effective amount of the composition of claim 27.
n

AU13013/95A
1993-12-07
1994-12-06
BMP-12, BMP-13 and tendon-inducing compositions thereof

Expired

AU689184B2
(en)

Applications Claiming Priority (7)

Application Number
Priority Date
Filing Date
Title

US16410393A

1993-12-07
1993-12-07

US164103

1993-12-07

US21778094A

1994-03-25
1994-03-25

US217780

1994-03-25

US08/333,576

US6027919A
(en)

1993-12-07
1994-11-02
BMP-12 and BMP-13 proteins and DNA encoding them

US333576

1994-11-02

PCT/US1994/014030

WO1995016035A2
(en)

1993-12-07
1994-12-06
Bmp-12, bmp-13 and tendon-inducing compositions thereof

Publications (2)

Publication Number
Publication Date

AU1301395A

AU1301395A
(en)

1995-06-27

AU689184B2
true

AU689184B2
(en)

1998-03-26

Family
ID=27388970
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU13013/95A
Expired

AU689184B2
(en)

1993-12-07
1994-12-06
BMP-12, BMP-13 and tendon-inducing compositions thereof

Country Status (15)

Country
Link

US
(5)

US5658882A
(en)

EP
(1)

EP0733109B9
(en)

JP
(3)

JP3717930B2
(en)

KR
(1)

KR100353182B1
(en)

AT
(1)

ATE319823T1
(en)

AU
(1)

AU689184B2
(en)

CA
(1)

CA2176942C
(en)

DE
(1)

DE69434651T2
(en)

DK
(1)

DK0733109T3
(en)

ES
(1)

ES2255059T3
(en)

FI
(1)

FI119816B
(en)

NO
(1)

NO317801B1
(en)

OA
(1)

OA10582A
(en)

PT
(1)

PT733109E
(en)

WO
(1)

WO1995016035A2
(en)

Families Citing this family (147)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US6150328A
(en)

*

1986-07-01
2000-11-21
Genetics Institute, Inc.
BMP products

US6586388B2
(en)

1988-04-08
2003-07-01
Stryker Corporation
Method of using recombinant osteogenic protein to repair bone or cartilage defects

US20070166353A1
(en)

*

1988-04-08
2007-07-19
Stryker Corporation
Osteogenic proteins

JP3504263B2
(en)

*

1991-11-04
2004-03-08
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー

Recombinant bone morphogenetic protein heterodimers, compositions and uses

US20080070842A1
(en)

*

1991-11-04
2008-03-20
David Israel
Recombinant bone morphogenetic protein heterodimers, compositions and methods of use

DE19525416A1
(en)

*

1995-07-12
1997-01-16
Bioph Biotech Entw Pharm Gmbh

Use of MP52 for the treatment and prevention of diseases of the nervous system

US20080233170A1
(en)

*

1992-02-21
2008-09-25
Stryker Corporation
Osteogenic Proteins

AU697625B2
(en)

*

1993-07-09
1998-10-15
Johns Hopkins University School Of Medicine, The
Growth differentiation factor-6

WO1995001802A1
(en)

1993-07-09
1995-01-19
The Johns Hopkins University School Of Medicine
Growth differentiation factor-7

US6291206B1
(en)

*

1993-09-17
2001-09-18
Genetics Institute, Inc.
BMP receptor proteins

DK0733109T3
(en)

*

1993-12-07
2006-07-03
Genetics Inst Llc

BMP-12, BMP-13 and late inducing preparations thereof

US5942496A
(en)

1994-02-18
1999-08-24
The Regent Of The University Of Michigan
Methods and compositions for multiple gene transfer into bone cells

US6551618B2
(en)

1994-03-15
2003-04-22
University Of Birmingham
Compositions and methods for delivery of agents for neuronal regeneration and survival

US5906827A
(en)

*

1994-06-03
1999-05-25
Creative Biomolecules, Inc.
Matrix for the manufacture of autogenous replacement body parts

AU1120295A
(en)

*

1994-11-07
1996-05-31
Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The
Cartilage-derived morphogenetic proteins

US20010011131A1
(en)

*

1997-07-28
2001-08-02
Luyten Frank P.
DNA molecules encoding cartilage-derived morphogenetic proteins

US5846770A
(en)

*

1994-11-22
1998-12-08
Genetics Institute, Inc.
DNA molecules encoding human chordin

HU225424B1
(en)

*

1995-04-19
2006-11-28
Bioph Biotech Entw Pharm Gmbh
Modified mp52-protein and process for producing thereof

PT831884E
(en)

*

1995-06-05
2003-11-28
New York Society

USE OF MORPHOGENETIC PROTEINS FROM THE CASE FOR HEALING AND REPARATION OF THE CONJUNCTIVE TISSUE CONNECTION

US5902785A
(en)

*

1995-06-06
1999-05-11
Genetics Institute, Inc.
Cartilage induction by bone morphogenetic proteins

ZA966489B
(en)

*

1995-08-03
1997-02-26
Bioph Biotech Entw Pharm Gmbh
New protein human MP52 Arg.

US7026292B1
(en)

1995-12-12
2006-04-11
Stryker Corporation
Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

US6048964A
(en)

*

1995-12-12
2000-04-11
Stryker Corporation
Compositions and therapeutic methods using morphogenic proteins and stimulatory factors

DE19548476A1
(en)

*

1995-12-22
1997-06-26
Bioph Biotech Entw Pharm Gmbh

Targeted connections with cartilage and / or bone inducing activity

US5700774A
(en)

*

1996-03-26
1997-12-23
Genetics Institute, Inc.
Compositions comprising bone morphogenic proteins and truncated parathyroid hormone related peptide, and methods of inducing cartilage by administration of same

US5965403A
(en)

*

1996-09-18
1999-10-12
Genetics Institute, Inc.
Nucleic acids encoding bone morphogenic protein-16 (BMP-16)

JPH11335398A
(en)

*

1998-05-22
1999-12-07
Hoechst Marion Roussel Kk
New monomeric protein having bone-inducing activity and preventive/therapeutic agent for chondropathy/ osteopathy consisting thereof

EP1074620A1
(en)

*

1999-08-06
2001-02-07
HyGene AG
Monomeric protein of the TGF-beta family

EP0957943B2
(en)

1997-02-07
2008-11-26
Stryker Corporation
Matrix-free osteogenic devices, implants and methods of use thereof

US7041641B2
(en)

1997-03-20
2006-05-09
Stryker Corporation
Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects

US20010016646A1
(en)

1998-03-20
2001-08-23
David C. Rueger
Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects

WO1998044874A1
(en)

1997-04-04
1998-10-15
Barnes-Jewish Hospital
Neocartilage and methods of use

EP0985149A1
(en)

1997-05-30
2000-03-15
Creative Biomolecules, Inc.
Methods for evaluating tissue morphogenesis and activity

EP0896825B1
(en)

1997-08-14
2002-07-17
Sulzer Innotec Ag
Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors

US6482584B1
(en)

*

1998-11-13
2002-11-19
Regeneration Technologies, Inc.
Cyclic implant perfusion cleaning and passivation process

US20010031254A1
(en)

*

1998-11-13
2001-10-18
Bianchi John R.
Assembled implant

US6281175B1
(en)

1997-09-23
2001-08-28
Scimed Life Systems, Inc.
Medical emulsion for lubrication and delivery of drugs

US20020052026A1
(en)

1997-10-08
2002-05-02
Steven M. Vicik
Methods of refolding proteins

IL136230A0
(en)

1997-11-28
2001-05-20
Roche Diagnostics Gmbh
An active hedgehog-protein-mutant, a process for its preparation and its use for pharmaceutical purposes

US6027917A
(en)

*

1997-12-10
2000-02-22
Genetics Institute, Inc.
Bone morphogenetic protein (BMP)-17 and BMP-18 compositions

ES2389387T3
(en)

1998-03-17
2012-10-25
Genentech, Inc.

Homologous VEGF and BMP1 polypeptides

US6541623B1
(en)

1998-04-03
2003-04-01
Hyseq, Inc.
Interleukin—1 receptor antagonist and uses thereof

US6294655B1
(en)

1998-04-03
2001-09-25
Hyseq, Inc.
Anti-interleukin-1 receptor antagonist antibodies and uses thereof

US6426191B1
(en)

1998-04-03
2002-07-30
Hyseq, Inc.
Assays involving an IL-1 receptor antagonist

US6337072B1
(en)

1998-04-03
2002-01-08
Hyseq, Inc.
Interleukin-1 receptor antagonist and recombinant production thereof

US7572440B2
(en)

1999-07-30
2009-08-11
Stryker Corporation
Method for repairing a defect in an intervertebral disc

MXPA01003538A
(en)

*

1998-10-06
2005-09-08
Rush Presbyterian St Luke
Method for the treatment of chemonucleolysis.

EP1649865B1
(en)

*

1998-10-06
2012-06-13
Stryker Corporation
GDF-5 for use in repairing a nonarticular cartilage defect in an intervertebral disc

US6958149B2
(en)

1998-10-06
2005-10-25
Stryker Corporation
Repair of larynx, trachea, and other fibrocartilaginous tissues

US6677432B1
(en)

1998-10-07
2004-01-13
Stryker Corporation
Mutations of the C-terminal portion of TGF-β superfamily proteins

US6846906B1
(en)

1998-10-07
2005-01-25
Stryker Corporation
Modified proteins of the TGF-β superfamily, including morphogenic proteins

CA2657302A1
(en)

*

1998-10-07
2000-04-13
Hermann Oppermann
Modified tgf-.beta. superfamily proteins

HU0105312A3
(en)

*

1999-02-01
2003-12-29
Genetics Inst Llc Cambridge
Methods and compositions for healing and repair of articular cartilage

US6727224B1
(en)

1999-02-01
2004-04-27
Genetics Institute, Llc.
Methods and compositions for healing and repair of articular cartilage

DE60036937T2
(en)

1999-04-28
2008-08-07
Genetics Institute, LLC, Cambridge

HUMANE GIL-19 / AE289 PROTEINS AND POLYNUCLEOTIDE CODING THEREOF

EP1054018B1
(en)

1999-05-18
2009-01-28
Dyax Corp.
Fab fragment libraries and methods for their use

US7189392B1
(en)

*

1999-10-15
2007-03-13
Genetics Institute, Llc
Injectable carrier formulations of hyaluronic acid derivatives for delivery of osteogenic proteins

US6368787B1
(en)

1999-12-16
2002-04-09
Stryker Corporation
Methods and compositions for identifying morphogenic protein analogs using morphogenic protein responsive inhibitory elements

ATE460951T1
(en)

*

2000-01-25
2010-04-15
Edwards Lifesciences Corp

RELEASE SYSTEMS FOR THE TREATMENT OF RESTENOSIS AND ANASTOMOTIC INTIMAL HYPERPLASIA

EP1261365B1
(en)

*

2000-03-09
2006-09-20
Zimmer Orthobiologics, Inc.
Product for biological anchoring of connective tissue to bone

US20030065140A1
(en)

*

2000-04-03
2003-04-03
Vernet Corine A.M.
Novel proteins and nucleic acids encoding same

EP2042597B1
(en)

2000-06-23
2014-05-07
Genentech, Inc.
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis

EP2075253A1
(en)

2000-06-23
2009-07-01
Genentech, Inc.
Compositions and methds for the diagnosis and treatment of disorders involving angiogensis

US7270730B2
(en)

*

2000-08-04
2007-09-18
Essen Instruments, Inc.
High-throughput electrophysiological measurement system

US7067046B2
(en)

2000-08-04
2006-06-27
Essen Instruments, Inc.
System for rapid chemical activation in high-throughput electrophysiological measurements

US20040010118A1
(en)

*

2000-08-16
2004-01-15
Zerhusen Bryan D.
Novel proteins and nucleic acids encoding same

US20030082233A1
(en)

*

2000-12-01
2003-05-01
Lyons Karen M.
Method and composition for modulating bone growth

WO2002076494A2
(en)

*

2001-03-23
2002-10-03
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS

DE60226321T2
(en)

*

2001-06-01
2009-07-09
Wyeth

COMPOSITIONS FOR THE SYSTEMIC ADMINISTRATION OF SEQUENCES THAT CODE FOR BONE MORPHOGENESIS PROTEINS

TWI267378B
(en)

2001-06-08
2006-12-01
Wyeth Corp
Calcium phosphate delivery vehicles for osteoinductive proteins

US20030087274A1
(en)

*

2001-07-05
2003-05-08
Anderson David W.
Therapeutic polypeptides, nucleic acids encoding same, and methods of use

DE60205937T3
(en)

2001-11-19
2016-01-21
Scil Technology Gmbh

Method for producing a homogeneously coated device with osteoinductive and osteoconductive properties

CH695985A5
(en)

2002-01-21
2006-11-15
Straumann Holding Ag
Surface-modified implants.

WO2003099992A2
(en)

*

2002-05-17
2003-12-04
Wyeth
Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins

US7622562B2
(en)

2002-06-26
2009-11-24
Zimmer Orthobiologics, Inc.
Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue

BR0313429A
(en)

2002-08-13
2007-07-31
Wyeth Corp

peptides as solubilizing excipients for transforming growth factor beta proteins

DE60304584T2
(en)

2002-09-10
2007-04-26
Scil Technology Gmbh

METAL IMPLANT COATED WITH REDUCED OXYGEN CONCENTRATION WITH AN OSTEOINDUCTIVE PROTEIN

ES2383328T3
(en)

2003-07-25
2012-06-20
Amgen, Inc

Methods related to LDCAM and CRTAM

PL1675608T3
(en)

2003-09-12
2007-11-30
Wyeth Corp
Injectable calcium phosphate solid rods for delivery of osteogenic proteins

US8328876B2
(en)

*

2003-12-31
2012-12-11
Warsaw Orthopedic, Inc.
Bone matrix compositions and methods

US8734525B2
(en)

2003-12-31
2014-05-27
Warsaw Orthopedic, Inc.
Osteoinductive demineralized cancellous bone

CA2557231C
(en)

*

2004-03-05
2013-12-31
The Trustees Of Columbia University In The City Of New York
Multi-phased, biodegradable and osteointegrative composite scaffold for biological fixation of musculoskeletal soft tissue to bone

DE602005022998D1
(en)

2004-03-10
2010-09-30
Scil Technology Gmbh

COATED IMPLANTS, THEIR MANUFACTURE AND USE THEREOF

WO2005116052A2
(en)

2004-04-27
2005-12-08
Research Development Foundation
ANTAGONISM OF TGF-β SUPERFAMILY RECEPTOR SIGNALING

ATE515268T1
(en)

2004-05-25
2011-07-15
Stryker Corp

USE OF OP-1 TO TREAT CARTILAGE DEFECTS

US8398638B2
(en)

*

2004-08-30
2013-03-19
Spineovations, Inc.
Method of treating spinal internal disk derangement

US8127770B2
(en)

*

2004-08-30
2012-03-06
Spineovations, Inc.
Method of using an implant for treament of ligaments and tendons

US7473678B2
(en)

2004-10-14
2009-01-06
Biomimetic Therapeutics, Inc.
Platelet-derived growth factor compositions and methods of use thereof

US20060166251A1
(en)

*

2005-01-26
2006-07-27
Archambault Joanne M
Use of sFRPs as markers of BMP activity

AU2006226941A1
(en)

*

2005-03-24
2006-09-28
Wyeth
Use of fibrous tissue inducing proteins for hernia repair

CA2601436A1
(en)

*

2005-03-30
2006-10-05
Wyeth
Methods for stimulating hair growth by administering bmps

US20060247790A1
(en)

*

2005-04-30
2006-11-02
Mckay William F
Shaped osteochondral grafts and methods of using same

US20060287676A1
(en)

*

2005-06-15
2006-12-21
Rita Prajapati
Method of intra-operative coating therapeutic agents onto sutures, composite sutures and methods of use

US20060286289A1
(en)

*

2005-06-15
2006-12-21
Rita Prajapati
Method of intraoperative coating therapeutic agents onto sutures

US20060287675A1
(en)

*

2005-06-15
2006-12-21
Prajapati Rita T
Method of intra-operative coating therapeutic agents onto sutures composite sutures and methods of use

US20060286171A1
(en)

*

2005-06-17
2006-12-21
Tianhong Zhou
Bone morphogenetic protein formulations

US20070056050A1
(en)

*

2005-06-29
2007-03-08
Clokie Cameron M L
PRODUCTION OF BONE MORPHOGENIC PROTEINS (BMPs) IN TRANSGENIC MAMMALS

CN101365499A
(en)

2005-11-01
2009-02-11
骨骼技术股份有限公司
Bone matrix compositions and methods

WO2007057212A1
(en)

*

2005-11-18
2007-05-24
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
High activity growth factor mutants

US8147860B2
(en)

2005-12-06
2012-04-03
Etex Corporation
Porous calcium phosphate bone material

ES2443581T3
(en)

2006-02-09
2014-02-19
Biomimetic Therapeutics, Llc

Compositions and methods for bone treatment

WO2007142818A2
(en)

2006-05-17
2007-12-13
Stryker Corporation
Use of a soluble morphogenic protein complex for treating cartilage defects

CA2656278C
(en)

2006-06-30
2016-02-09
Biomimetic Therapeutics, Inc.
Compositions and methods for treating rotator cuff injuries

US9161967B2
(en)

2006-06-30
2015-10-20
Biomimetic Therapeutics, Llc
Compositions and methods for treating the vertebral column

US8524265B2
(en)

2006-08-17
2013-09-03
Warsaw Orthopedic, Inc.
Medical implant sheets useful for tissue regeneration

US20100047309A1
(en)

*

2006-12-06
2010-02-25
Lu Helen H
Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods

AU2007234612B2
(en)

2006-12-14
2013-06-27
Johnson & Johnson Regenerative Therapeutics, Llc
Protein stabilization formulations

JP5452230B2
(en)

2006-12-21
2014-03-26
ストライカー コーポレイション

Sustained release formulations comprising biological agent crystals, polymer gels and particle suspensions

US8753391B2
(en)

2007-02-12
2014-06-17
The Trustees Of Columbia University In The City Of New York
Fully synthetic implantable multi-phased scaffold

EP2167665A4
(en)

*

2007-05-25
2010-12-29
Induce Biolog Inc
A method of enhancing recombinant protein production

US20080299172A1
(en)

*

2007-06-04
2008-12-04
Stuart Young
Tissue repair implant

CA2945295C
(en)

2007-06-15
2020-01-14
Warsaw Orthopedic, Inc.
Method of treating tissue

AU2008265850B2
(en)

2007-06-15
2014-06-26
Warsaw Orthopedic, Inc.
Bone matrix compositions and methods

US9554920B2
(en)

2007-06-15
2017-01-31
Warsaw Orthopedic, Inc.
Bone matrix compositions having nanoscale textured surfaces

US7678764B2
(en)

2007-06-29
2010-03-16
Johnson & Johnson Regenerative Therapeutics, Llc
Protein formulations for use at elevated temperatures

WO2009009688A1
(en)

2007-07-10
2009-01-15
Osteotech, Inc.
Delivery system

EP2019117A1
(en)

*

2007-07-27
2009-01-28
BIOPHARM GESELLSCHAFT ZUR BIOTECHNOLOGISCHEN ENTWICKLUNG VON PHARMAKA mbH
Optimized purification process of recombinant growth factor protein

WO2009020744A1
(en)

2007-08-07
2009-02-12
Johnson & Johnson Regenerative Therapeutics, Llc
Protein formulations comprising gdf-5 in aqueous acidic solution

ES2446544T3
(en)

*

2007-10-19
2014-03-10
Warsaw Orthopedic, Inc.

Demineralized bone matrix compositions and methods

CA2718592A1
(en)

2008-02-13
2009-08-20
Keith Hruska
Method of treating vascular sclerosis

US20100010549A1
(en)

*

2008-03-05
2010-01-14
Neville Alleyne
device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries

US8469961B2
(en)

*

2008-03-05
2013-06-25
Neville Alleyne
Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints

US20100004700A1
(en)

*

2008-03-05
2010-01-07
Neville Alleyne
Method of treating tissue with a suspenson of tricalcium hydroxyapatite microspheres

BRPI0911048A2
(en)

2008-04-14
2015-12-29
Atrm Llc

gdf-5 buffered liquid formulations

US20100004175A1
(en)

*

2008-06-09
2010-01-07
Tanya Shang
Novel bmp-12-related proteins and methods of their manufacture

JP5816553B2
(en)

2008-09-09
2015-11-18
バイオミメティック セラピューティクス， エルエルシー

Platelet-derived growth factor compositions and methods for treating tendon or ligament injury

SG173634A1
(en)

2009-02-12
2011-09-29
Stryker Corp
COMPOSITIONS AND METHODS FOR MINIMALLY-INVASIVE SYSTEMIC DELIVERY OF PROTEINS INCLUDING TGF-ß SUPERFAMILY MEMBERS

US9220598B2
(en)

2009-02-12
2015-12-29
Warsaw Orthopedic, Inc.
Delivery systems, tools, and methods of use

CA2752157A1
(en)

2009-02-12
2010-08-19
Stryker Corporation
Peripheral administration of proteins including tgf-.beta. superfamily members for systemic treatment of disorders and disease

WO2010110974A1
(en)

2009-03-24
2010-09-30
Stryker Corporation
Methods and compositions for tissue engineering

US8609127B2
(en)

2009-04-03
2013-12-17
Warsaw Orthopedic, Inc.
Medical implant with bioactive material and method of making the medical implant

WO2010144696A1
(en)

2009-06-11
2010-12-16
Burnham Institute For Medical Research
Directed differentiation of stem cells

US20110224138A1
(en)

2009-09-09
2011-09-15
Julie Krop
Methods for treating pain induced by injuries and diseases of an articular joint

AU2010295509A1
(en)

2009-09-17
2012-04-19
Stryker Corporation
Buffers for controlling the pH of bone morphogenetic proteins

US8657859B2
(en)

2009-12-16
2014-02-25
Advanced Veterinary Solutions
Implant for promoting stability of the canine stifle joint

AU2010341565A1
(en)

2009-12-22
2012-07-12
Stryker Corporation
BMP-7 variants with reduced immunogenicity

CA2790403C
(en)

2010-02-22
2019-08-27
Biomimetic Therapeutics, Inc.
Platelet-derived growth factor compositions and methods for the treatment of tendinopathies

CA2806143A1
(en)

2010-07-30
2012-02-02
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mb H
Drug delivery devices and growth factor formulations for accelerated wound healing

EP2537538A1
(en)

2011-06-22
2012-12-26
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH
Bioresorbable Wound Dressing

EP2602264A1
(en)

2011-12-05
2013-06-12
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka mbH
GDF-5 mutant for inducing cartilage formation

WO2014012101A1
(en)

2012-07-13
2014-01-16
Trustees Of Tufts College
Silk powder compaction for production of constructs with high mechanical strength and stiffness

EP2983643A4
(en)

2013-04-12
2016-12-28
Univ Columbia
Methods for host cell homing and dental pulp regeneration

CA2973727A1
(en)

2015-01-16
2016-07-21
Spineovations, Inc.
Method of treating spinal disk

CN108430458B
(en)

2015-10-26
2022-05-10
哈佛学院院长等
Reduced and oxidized polysaccharides and methods of use thereof

KR101659796B1
(en)

2016-01-13
2016-10-10
주식회사 셀루메드
Mixture of bmp proteins at specific ratios

US20190328792A1
(en)

*

2017-01-11
2019-10-31
Paracelsus Medizinische Privatuniversität Salzburg – Privatstiftung
Mesenchymal stem cell-derived extracellular vesicles and their medical use

WO2021122545A1
(en)

2019-12-18
2021-06-24
Merck Patent Gmbh
Use of the gdf-5 mutant for the treatment of pain and cartilage destruction

Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

WO1991018047A2
(en)

*

1990-05-24
1991-11-28

Genentech, Inc.

Mammalian expression of the bmp-2 family

WO1993000432A1
(en)

*

1991-06-25
1993-01-07

Genetics Institute, Inc.

Bmp-9 compositions

WO1993016099A2
(en)

*

1992-02-12
1993-08-19

Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh

Dna sequences encoding novel growth/differentiation factors

Family Cites Families (133)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US2465357A
(en)

1944-08-14
1949-03-29
Upjohn Co
Therapeutic sponge and method of making

CH563767A5
(en)

1973-01-30
1975-07-15
Pheulpin Jean

US4468464A
(en)

1974-11-04
1984-08-28
The Board Of Trustees Of The Leland Stanford Junior University
Biologically functional molecular chimeras

DE2657370C2
(en)

1976-12-17
1982-11-11
Hans Dr.med. Dr.med.dent. 8000 München Scheicher

Means for covering and / or filling in bone defects

DE2732848A1
(en)

1977-07-18
1979-02-08
Schering Ag

DIURETHANE, HERBICIDAL AGENTS CONTAINING THESE COMPOUNDS AND THE PROCESS FOR THEIR PRODUCTION

US4399216A
(en)

1980-02-25
1983-08-16
The Trustees Of Columbia University
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials

US4619989A
(en)

1981-05-05
1986-10-28
The Regents Of The University Of Cal.
Bone morphogenetic protein composition

US4294753A
(en)

*

1980-08-04
1981-10-13
The Regents Of The University Of California
Bone morphogenetic protein process

US4761471A
(en)

*

1980-08-04
1988-08-02
The Regents Of The University Of California
Bone morphogenetic protein composition

US4455256A
(en)

1981-05-05
1984-06-19
The Regents Of The University Of California
Bone morphogenetic protein

US4789732A
(en)

1980-08-04
1988-12-06
Regents Of The University Of California
Bone morphogenetic protein composition

US4419446A
(en)

1980-12-31
1983-12-06
The United States Of America As Represented By The Department Of Health And Human Services
Recombinant DNA process utilizing a papilloma virus DNA as a vector

IE52535B1
(en)

1981-02-16
1987-12-09
Ici Plc
Continuous release pharmaceutical compositions

US4727028A
(en)

1981-06-22
1988-02-23
Eli Lilly And Company
Recombinant DNA cloning vectors and the eukaryotic and prokaryotic transformants thereof

US4394370A
(en)

1981-09-21
1983-07-19
Jefferies Steven R
Bone graft material for osseous defects and method of making same

US4472840A
(en)

1981-09-21
1984-09-25
Jefferies Steven R
Method of inducing osseous formation by implanting bone graft material

US4474181A
(en)

1982-02-18
1984-10-02
Schenck Robert R
Method and apparatus for anastomosing small blood vessels

US4455526A
(en)

*

1982-06-29
1984-06-19
The United States Of America As Represented By The Secretary Of The Air Force
FET Switching regulator

DE3382562D1
(en)

1982-09-24
1992-06-25
Us Health

ANIMAL TISSUE RECOVERY.

IL68218A
(en)

1983-03-23
1985-12-31
Univ Ramot
Compositions for cartilage repair comprising embryonal chondrocytes

US4434094A
(en)

*

1983-04-12
1984-02-28
Collagen Corporation
Partially purified osteogenic factor and process for preparing same from demineralized bone

US4795804A
(en)

1983-08-16
1989-01-03
The Regents Of The University Of California
Bone morphogenetic agents

US4923805A
(en)

1983-11-02
1990-05-08
Integrated Genetics, Inc.
Fsh

US4703008A
(en)

1983-12-13
1987-10-27
Kiren-Amgen, Inc.
DNA sequences encoding erythropoietin

GB8334498D0
(en)

1983-12-24
1984-02-01
Beecham Group Plc
Compounds

US4804744A
(en)

*

1984-01-04
1989-02-14
International Genetic Engineering, Inc.
Osteogenic factors

US4608199A
(en)

1984-03-20
1986-08-26
Arnold Caplan
Bone protein purification process

US4662884A
(en)

1984-04-25
1987-05-05
University Of Utah Research Foundation
Prostheses and methods for promoting nerve regeneration

US4596574A
(en)

1984-05-14
1986-06-24
The Regents Of The University Of California
Biodegradable porous ceramic delivery system for bone morphogenetic protein

CA1341617C
(en)

1984-06-08
2011-06-28
Henry George Burger
Inhibin isolated from ovarian follicular fluid

US4868161A
(en)

1984-06-29
1989-09-19
City Of Hope
Method for promoting nerve regeneration

US4627982A
(en)

*

1984-07-16
1986-12-09
Collagen Corporation
Partially purified bone-inducing factor

US4843063A
(en)

1984-07-16
1989-06-27
Collagen Corporation
Polypeptide cartilage-inducing factors found in bone

ATE128715T1
(en)

1984-07-16
1995-10-15
Celtrix Pharma

POLYPEPTIDE-INDUCING FACTORS IN BONE AND CARTILAGE.

EP0177343B1
(en)

1984-10-05
1992-07-22
Genentech, Inc.
Dna, cell cultures and methods for the secretion of heterologous proteins and periplasmic protein recovery

US4769328A
(en)

1984-10-12
1988-09-06
Zymogenetics Inc.
Expression of biologically active PDGF analogs in yeast

US5187263A
(en)

1984-10-12
1993-02-16
Zymogenetics, Inc.
Expression of biologically active PDGE analogs in eucaryotic cells

US4563350A
(en)

*

1984-10-24
1986-01-07
Collagen Corporation
Inductive collagen based bone repair preparations

AU598455B2
(en)

1984-12-27
1990-06-28
Suntory Limited
Method for purifying an interferon

US4886747A
(en)

1985-03-22
1989-12-12
Genentech, Inc.
Nucleic acid encoding TGF-β and its uses

US4766067A
(en)

1985-05-31
1988-08-23
President And Fellows Of Harvard College
Gene amplification

US4681763A
(en)

1985-06-11
1987-07-21
University Of Medicine And Dentistry Of New Jersey
Composition for stimulating bone growth

US4851521A
(en)

1985-07-08
1989-07-25
Fidia, S.P.A.
Esters of hyaluronic acid

US5215893A
(en)

1985-10-03
1993-06-01
Genentech, Inc.
Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid

US5089396A
(en)

1985-10-03
1992-02-18
Genentech, Inc.
Nucleic acid encoding β chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid

US4798885A
(en)

1986-02-07
1989-01-17
Genentech, Inc.
Compositions of hormonally active human and porcine inhibin containing an α chain and 62 chain

US4737578A
(en)

1986-02-10
1988-04-12
The Salk Institute For Biological Studies
Human inhibin

US4758233A
(en)

1986-04-22
1988-07-19
N.J. Phillips TPY. Limited
Cream applicator

NL8601328A
(en)

1986-05-23
1987-12-16
Langen Research

DEVICE FOR INJECTING MEAT WITH A MASS, PARTICULARLY PASTY MASS.

US5108922A
(en)

*

1986-07-01
1992-04-28
Genetics Institute, Inc.
DNA sequences encoding BMP-1 products

US5631142A
(en)

*

1986-07-01
1997-05-20
Genetics Institute, Inc.
Compositions comprising bone morphogenetic protein-2 (BMP-2)

US6150328A
(en)

*

1986-07-01
2000-11-21
Genetics Institute, Inc.
BMP products

US4877864A
(en)

*

1987-03-26
1989-10-31
Genetics Institute, Inc.
Osteoinductive factors

ZA874681B
(en)

*

1986-07-01
1988-04-27
Genetics Inst
Novel osteoinductive factors

US5013649A
(en)

*

1986-07-01
1991-05-07
Genetics Institute, Inc.
DNA sequences encoding osteoinductive products

US5187076A
(en)

*

1986-07-01
1993-02-16
Genetics Institute, Inc.
DNA sequences encoding BMP-6 proteins

US5106748A
(en)

*

1986-07-01
1992-04-21
Genetics Institute, Inc.
Dna sequences encoding 5 proteins

US6432919B1
(en)

*

1986-07-01
2002-08-13
Genetics Institute, Inc.
Bone morphogenetic protein-3 and compositions

US5459047A
(en)

*

1986-07-01
1995-10-17
Genetics Institute, Inc.
BMP-6 proteins

US5543394A
(en)

*

1986-07-01
1996-08-06
Genetics Institute, Inc.
Bone morphogenetic protein 5(BMP-5) compositions

US5019087A
(en)

1986-10-06
1991-05-28
American Biomaterials Corporation
Nerve regeneration conduit

US5124316A
(en)

1986-11-14
1992-06-23
President And Fellows Of Harvard College
Method for periodontal regeneration

US5041538A
(en)

1987-08-28
1991-08-20
The Salk Institute For Biological Studies
Mammalian follistatin

US5202120A
(en)

1987-09-11
1993-04-13
Case Western Reserve University
Methods of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes

US5147399A
(en)

1988-02-01
1992-09-15
Dellon Arnold L
Method of treating nerve defects through use of a bioabsorbable surgical device

EP0336760A3
(en)

*

1988-04-06
1991-03-13
Celtrix Pharmaceuticals, Inc.
Bone-inducing protein

US4968590A
(en)

*

1988-04-08
1990-11-06
Stryker Corporation
Osteogenic proteins and polypeptides

US5258494A
(en)

*

1988-04-08
1993-11-02
Stryker Corporation
Osteogenic proteins

US5266683A
(en)

1988-04-08
1993-11-30
Stryker Corporation
Osteogenic proteins

US5354557A
(en)

1988-04-08
1994-10-11
Stryker Corporation
Osteogenic devices

US6586388B2
(en)

*

1988-04-08
2003-07-01
Stryker Corporation
Method of using recombinant osteogenic protein to repair bone or cartilage defects

US5108753A
(en)

1988-04-08
1992-04-28
Creative Biomolecules
Osteogenic devices

US5011691A
(en)

1988-08-15
1991-04-30
Stryker Corporation
Osteogenic devices

US5024841A
(en)

1988-06-30
1991-06-18
Collagen Corporation
Collagen wound healing matrices and process for their production

US5071834A
(en)

1988-09-16
1991-12-10
Genentech, Inc.
Purified activin B composition

US5106626A
(en)

1988-10-11
1992-04-21
International Genetic Engineering, Inc.
Osteogenic factors

US5284756A
(en)

*

1988-10-11
1994-02-08
Lynn Grinna
Heterodimeric osteogenic factor

US4955892A
(en)

1988-10-24
1990-09-11
Louisiana State University
Neural cell adhesion protein nerve prosthesis

US5457038A
(en)

*

1988-11-10
1995-10-10
Genetics Institute, Inc.
Natural killer stimulatory factor

US5011486A
(en)

1988-11-18
1991-04-30
Brown University Research Foundation
Composite nerve guidance channels

US5162430A
(en)

1988-11-21
1992-11-10
Collagen Corporation
Collagen-polymer conjugates

US4920962A
(en)

1988-11-23
1990-05-01
Claude Proulx
Splint-like element for use in end-to-end nerve suture

US5217867A
(en)

1988-11-30
1993-06-08
The Salk Institute For Biological Studies
Receptors: their identification, characterization, preparation and use

US4963146A
(en)

1989-04-20
1990-10-16
Colla-Tec Incorporated
Multi-layered, semi-permeable conduit for nerve regeneration

US5026381A
(en)

1989-04-20
1991-06-25
Colla-Tec, Incorporated
Multi-layered, semi-permeable conduit for nerve regeneration comprised of type 1 collagen, its method of manufacture and a method of nerve regeneration using said conduit

US5166322A
(en)

1989-04-21
1992-11-24
Genetics Institute
Cysteine added variants of interleukin-3 and chemical modifications thereof

CA2017466A1
(en)

*

1989-06-02
1990-12-02
Michael C. Kiefer
Bone calcification factor

US5399346A
(en)

*

1989-06-14
1995-03-21
The United States Of America As Represented By The Department Of Health And Human Services
Gene therapy

AU5958090A
(en)

1989-06-29
1991-01-17
United States of America, as represented by the Secretary, U.S. Department of Commerce, The
Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1

CA2020729A1
(en)

*

1989-07-19
1991-01-20
Michael C. Kiefer
Bone morphogenetic protein

US5324519A
(en)

1989-07-24
1994-06-28
Atrix Laboratories, Inc.
Biodegradable polymer composition

US5422340A
(en)

*

1989-09-01
1995-06-06
Ammann; Arthur J.
TGF-βformulation for inducing bone growth

ATE140965T1
(en)

*

1989-09-06
1996-08-15
Takeda Chemical Industries Ltd

PROTEIN, DNA AND THEIR USE

US5236456A
(en)

*

1989-11-09
1993-08-17
Osteotech, Inc.
Osteogenic composition and implant containing same

GB8927546D0
(en)

*

1989-12-06
1990-02-07
Ciba Geigy
Process for the production of biologically active tgf-beta

US5166190A
(en)

1990-01-08
1992-11-24
Genentech, Inc.
Method for increasing fertility in males

US5256418A
(en)

1990-04-06
1993-10-26
Organogenesis, Inc.
Collagen constructs

US5290271A
(en)

1990-05-14
1994-03-01
Jernberg Gary R
Surgical implant and method for controlled release of chemotherapeutic agents

DK0536186T3
(en)

*

1990-05-16
2002-05-21
Genetics Inst

Bone and cartilage-forming proteins

US5218090A
(en)

1990-06-12
1993-06-08
Warner-Lambert Company
EGF receptor truncates

US5206028A
(en)

1991-02-11
1993-04-27
Li Shu Tung
Dense collagen membrane matrices for medical uses

US5208219A
(en)

*

1991-02-14
1993-05-04
Celtrix Pharmaceuticals Inc.
Method for inducing bone growth

US5318898A
(en)

*

1991-04-02
1994-06-07
Genetics Institute, Inc.
Production of recombinant bone-inducing proteins

US5118667A
(en)

1991-05-03
1992-06-02
Celtrix Pharmaceuticals, Inc.
Bone growth factors and inhibitors of bone resorption for promoting bone formation

US5229495A
(en)

1991-06-18
1993-07-20
Ludwig Institute For Cancer Research
Substantially pure receptor like TGF-β 1 binding molecules and uses thereof

US5216126A
(en)

1991-06-19
1993-06-01
Genentech, Inc.
Receptor polypeptides and their production and uses

DE69213739T2
(en)

1991-06-21
1997-02-20
Genetics Inst

MEDICINAL PRODUCTS CONTAINING OSTEOGENIC PROTEINS

US5306307A
(en)

1991-07-22
1994-04-26
Calcitek, Inc.
Spinal disk implant

US5171579A
(en)

1991-10-11
1992-12-15
Genetics Institute, Inc.
Formulations of blood clot-polymer matrix for delivery of osteogenic proteins

JP3504263B2
(en)

*

1991-11-04
2004-03-08
ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー

Recombinant bone morphogenetic protein heterodimers, compositions and uses

EP0627899B1
(en)

1992-02-28
2001-11-07
Cohesion Technologies, Inc.
Injectable ceramic compositions and methods for their preparation and use

WO1993019177A1
(en)

*

1992-03-18
1993-09-30
The General Hospital Corporation
FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY

JP3645258B2
(en)

*

1993-01-12
2005-05-11
ジョーンズ ホプキンス ユニバーシティー スクール オブ メディシン

Growth and differentiation factor-5

GB9308060D0
(en)

*

1993-04-19
1993-06-02
Cancer Res Campaign Tech
Stem cell inhibitor

PT1378572E
(en)

*

1993-05-12
2007-01-31
Genetics Inst
Bmp-11 compositions

US5637480A
(en)

*

1993-05-12
1997-06-10
Genetics Institute, Inc.
DNA molecules encoding bone morphogenetic protein-10

US5447725A
(en)

*

1993-06-11
1995-09-05
The Procter & Gamble Company
Methods for aiding periodontal tissue regeneration

KR100294026B1
(en)

*

1993-06-24
2001-09-17
야마자끼 순페이

Electro-optical device

AU697625B2
(en)

*

1993-07-09
1998-10-15
Johns Hopkins University School Of Medicine, The
Growth differentiation factor-6

WO1995001802A1
(en)

*

1993-07-09
1995-01-19
The Johns Hopkins University School Of Medicine
Growth differentiation factor-7

DE69434739T2
(en)

*

1993-08-26
2007-05-10
Genetics Institute, LLC, Cambridge

Human bone morphogenetic proteins for use in neuronal degeneration

US5455041A
(en)

*

1993-09-13
1995-10-03
Research Foundation Of State University Of New York At Buffalo
Method for inducing periodontal tissue regeneration

US6027919A
(en)

*

1993-12-07
2000-02-22
Genetics Institute, Inc.
BMP-12 and BMP-13 proteins and DNA encoding them

DK0733109T3
(en)

*

1993-12-07
2006-07-03
Genetics Inst Llc

BMP-12, BMP-13 and late inducing preparations thereof

US5399677A
(en)

*

1993-12-07
1995-03-21
Genetics Institute, Inc.
Mutants of bone morphogenetic proteins

US5723331A
(en)

*

1994-05-05
1998-03-03
Genzyme Corporation
Methods and compositions for the repair of articular cartilage defects in mammals

US5520923A
(en)

*

1994-09-19
1996-05-28
Genetics Institute, Inc.
Formulations for delivery of osteogenic proteins

US5635372A
(en)

*

1995-05-18
1997-06-03
Genetics Institute, Inc.
BMP-15 compositions

PT831884E
(en)

*

1995-06-05
2003-11-28
New York Society

USE OF MORPHOGENETIC PROTEINS FROM THE CASE FOR HEALING AND REPARATION OF THE CONJUNCTIVE TISSUE CONNECTION

US5752974A
(en)

*

1995-12-18
1998-05-19
Collagen Corporation
Injectable or implantable biomaterials for filling or blocking lumens and voids of the body

US6034062A
(en)

*

1997-03-13
2000-03-07
Genetics Institute, Inc.
Bone morphogenetic protein (BMP)-9 compositions and their uses

IT1302534B1
(en)

*

1998-12-21
2000-09-05
Fidia Advanced Biopolymers Srl

INJECTABLE, BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITIONS INCLUDING AT LEAST A DERIVATIVE OF HYALURONIC ACID, CHONDROGENIC CELLS, FOR

US6420243B1
(en)

*

2000-12-04
2002-07-16
Motorola, Inc.
Method for producing SOI wafers by delamination

1994

1994-12-06
DK
DK95904255T
patent/DK0733109T3/en
active

1994-12-06
DE
DE69434651T
patent/DE69434651T2/en
not_active
Expired – Lifetime

1994-12-06
CA
CA2176942A
patent/CA2176942C/en
not_active
Expired – Lifetime

1994-12-06
ES
ES95904255T
patent/ES2255059T3/en
not_active
Expired – Lifetime

1994-12-06
JP
JP51629395A
patent/JP3717930B2/en
not_active
Expired – Lifetime

1994-12-06
AU
AU13013/95A
patent/AU689184B2/en
not_active
Expired

1994-12-06
WO
PCT/US1994/014030
patent/WO1995016035A2/en
active
IP Right Grant

1994-12-06
AT
AT95904255T
patent/ATE319823T1/en
active

1994-12-06
PT
PT95904255T
patent/PT733109E/en
unknown

1994-12-06
EP
EP95904255A
patent/EP0733109B9/en
not_active
Expired – Lifetime

1994-12-22
US
US08/362,670
patent/US5658882A/en
not_active
Expired – Lifetime

1996

1996-06-04
NO
NO19962304A
patent/NO317801B1/en
not_active
IP Right Cessation

1996-06-06
FI
FI962350A
patent/FI119816B/en
not_active
IP Right Cessation

1996-06-07
OA
OA60840A
patent/OA10582A/en
unknown

1997

1997-02-28
US
US08/808,324
patent/US6284872B1/en
not_active
Expired – Lifetime

1999

1999-05-26
KR
KR1019990019060A
patent/KR100353182B1/en
not_active
IP Right Cessation

2001

2001-08-31
US
US09/945,182
patent/US6719968B2/en
not_active
Expired – Fee Related

2004

2004-02-18
US
US10/779,635
patent/US6984623B2/en
not_active
Expired – Fee Related

2005

2005-06-08
JP
JP2005168624A
patent/JP3939729B2/en
not_active
Expired – Lifetime

2005-06-17
US
US11/154,826
patent/US7365052B2/en
not_active
Expired – Fee Related

2006

2006-08-10
JP
JP2006218531A
patent/JP2007016037A/en
active
Pending

Patent Citations (3)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

WO1991018047A2
(en)

*

1990-05-24
1991-11-28
Genentech, Inc.
Mammalian expression of the bmp-2 family

WO1993000432A1
(en)

*

1991-06-25
1993-01-07
Genetics Institute, Inc.
Bmp-9 compositions

WO1993016099A2
(en)

*

1992-02-12
1993-08-19
Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh
Dna sequences encoding novel growth/differentiation factors

Also Published As

Publication number
Publication date

WO1995016035A2
(en)

1995-06-15

CA2176942A1
(en)

1995-06-15

FI119816B
(en)

2009-03-31

US20020160494A1
(en)

2002-10-31

EP0733109A1
(en)

1996-09-25

US6284872B1
(en)

2001-09-04

JPH09506261A
(en)

1997-06-24

FI962350A0
(en)

1996-06-06

KR100353182B1
(en)

2002-09-28

DE69434651D1
(en)

2006-05-04

EP0733109B1
(en)

2006-03-08

JP2005312457A
(en)

2005-11-10

US6719968B2
(en)

2004-04-13

ATE319823T1
(en)

2006-03-15

CA2176942C
(en)

2011-11-01

WO1995016035A3
(en)

1995-07-13

NO962304L
(en)

1996-06-04

US6984623B2
(en)

2006-01-10

NO317801B1
(en)

2004-12-13

US20070004005A1
(en)

2007-01-04

JP2007016037A
(en)

2007-01-25

NO962304D0
(en)

1996-06-04

DK0733109T3
(en)

2006-07-03

US5658882A
(en)

1997-08-19

EP0733109B9
(en)

2006-07-05

ES2255059T3
(en)

2006-06-16

PT733109E
(en)

2006-07-31

OA10582A
(en)

2002-08-23

JP3717930B2
(en)

2005-11-16

JP3939729B2
(en)

2007-07-04

FI962350A
(en)

1996-07-16

DE69434651T2
(en)

2007-03-08

US20040146923A1
(en)

2004-07-29

US7365052B2
(en)

2008-04-29

AU1301395A
(en)

1995-06-27

Similar Documents

Publication
Publication Date
Title

AU689184B2
(en)

1998-03-26

BMP-12, BMP-13 and tendon-inducing compositions thereof

WO1995016035A9
(en)

1995-09-14

Bmp-12, bmp-13 and tendon-inducing compositions thereof

US6027919A
(en)

2000-02-22

BMP-12 and BMP-13 proteins and DNA encoding them

AU692709B2
(en)

1998-06-11

BMP-15 compositions

KR100259827B1
(en)

2000-06-15

Recombinant bone morphogenetic protein heterodimers

KR100255415B1
(en)

2000-05-01

Bone morphogenetic protein-9 compositions

EP0698095B1
(en)

2004-04-28

Bmp-10 compositions

US5637480A
(en)

1997-06-10

DNA molecules encoding bone morphogenetic protein-10

ES2274157T3
(en)

2007-05-16

BMP-11 COMPOSITIONS.

ES2213927T3
(en)

2004-09-01

BMP-11 NEURONAL USES.

TW464690B
(en)

2001-11-21

Tendon-inducing compositions utilizing BMP-12 related bone morphogenetic proteins

ES2367035T3
(en)

2011-10-27

BMP-12, BMP-13 AND COMPOSITIONS OF THE SAME TO INDUCE TENDONS.

KR100247216B1
(en)

2000-03-15

Osteioinductive compositions

Legal Events

Date
Code
Title
Description

2003-02-20
HB
Alteration of name in register

Owner name:
GENETICS INSTITUTE, LLC, PRESIDENT AND FELLOWS OF

Free format text:
FORMER NAME WAS: GENETICS INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE

Download PDF in English